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Abstract 
Autoimmune diseases result from inappropriate self-
reactivity by lymphocytes. The long-term goal is to 
generate specific therapies for autoimmune diseases of 
humans, the success of which hinges on the definition of 
specific therapeutic targets. Experimental allergic 
encephalomyelitis (EAE) is a good animal model for the human 
demyelinating autoimmune disease, multiple sclerosis (MS). 
Risk for these diseases stratifies by major 
histocompatibility complex (MHC) allele, as well as by T 
cell receptor (TCR) locus RFLP, in the case of MS. These 
data suggest that (TCR-self peptide-MHC) complexes are 
associated, possibly causally, with pathogenesis. This work 
focused on the self peptide and TCR components of this 
complex. One specific aim was to document and characterize 
the T cell epitopes of the autoantigen, myelin basic protein 
(MBP), in the EAE-susceptible mouse strain, BIO.PL. Inbred 
BIO.PL mice which were immunized with self MBP in complete 
Freund's adjuvant activated lymphocytes specific for 
epitopes estimated by peptides MBP(NAcl-20), MBP(31-50), and 
MBP(121-140). These mice generated the bulk of their immune 
response to the MBP(NAcl-20) epitope. The responses to self 
MBP immunization of BIO.PL wildtype and MBP null "shiverer" 
mice were compared, and it was found that MBP(12I-140) is 
tolerogenic in animals which express MBP. A similar result 
v 
was observed in BALBjc wildtype and shiverer mice. These 
data demonstrate that MBP is not a sequestered antigen, that 
multiple epitopes tolerize T cells independently, and that 
incomplete, rather than absent, tolerance is present in mice 
susceptible to EAE. A second specific aim was to document 
the degree of variation in the primate TCR Vp 8 subfamily, 
three members of which are adjacent to a BamHI RFLP 
restriction site linked to multiple sclerosis (MS) disease 
risk. Vp 8.1 and 8.2 were compared in a number of primates. 
It was found that the overall coding sequences, but not the 
CDR coding sequences, were conserved compared with adjacent 
non-coding flanking sequences. CDR coding sequences were 
not demonstrably positively selected compared with non-
coding flanking sequences or with synonymous coding 
sequences. A comparison of unrelated normal humans failed 
to demonstrate any non-synonymous SUbstitutions within Vp 
8.1 and 8.2, and demonstrated a single non-synonymous 
SUbstitution in Vp 8.3. These data demonstrate that 
germline Vp 8 gene segments are conserved and minimally 
polymorphic, implying that final TCR protein diversity 
derives from other mechanisms. occasional allelism has been 
demonstrated in other Vp subfamilies, and our data does not 
rule out that certain TCR Vp alleles may ultimately be found 
to contribute to autoimmunity disease risk. 
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Vertebrate survival hinges on the ability of 
lymphocytes to anticipate, distinguish and destroy pathogens 
(Klein 1990). Because this set of pathogens is diverse, the 
set of clonal antigen specificities of lymphocytes is 
expected to be diverse as well. It is predicted that this 
diverse set of antigen specificities of lymphocytes is 
generated in a random fashion without regard to self-nonself 
distinctions. Lymphocyte antigen specificities includes 
self-specificities, so that tolerance to self must be 
acquired. Tolerance occasionally fails and lymphocyte self-
reactivity, or autoimmunity, results. Risk for autoimmunity 
stratifies by MHC allele and, in some diseases, by T cell 
antigen receptor (TCR) loci RFLPs. This suggests that 
pathogenic (MHC/TCR/self-peptide) complexes exist which are 
necessary, although not necessarily sufficient, for self-
reactive T cell activation and T cell-mediated injury. 
Unanswered questions include the degree to which self-
proteins and germline TCR V gene segments can be utilized in 
disease induction and progression. The purpose of this 
thesis was to attempt to answer these questions for the 
autoimmune demyelinating diseases. Specifically, it sought 
to determine the nature of the murine response to myelin 
basic protein (MBP) , the auto-antigen of experimental 
allergic encephalomyelitis (EAE) , and the breadth of 
variation in human TCR Vp 8, a subfamily which has been 
linked epidemiologically to a similar demyelinating disease 
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of humans, multiple sclerosis (MS). 
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Nonnal Lvmphocytes 
Lymphocytes are mobile, antigen-specific, non-
phagocytic leukocytes. In mammals, lymphocytes are derived 
from hemopoietic stem cells which mature in one of two 
primary lymphoid organs, the bone marrow (for B lymphocytes) 
and thymus (for T lymphocytes). Mature lymphocytes 
circulate from bloodstream to lymphatics via the secondary 
lymphoid organs, the spleen and lymph nodes. Splenic 
lymphocytes are exposed to blood-borne antigens, and lymph 
node lymphocytes are exposed to lymph-borne antigens. After 
exiting the secondary lymphoid organs into efferent 
lymphatics, they eventually re-enter the bloodstream. This 
traffic pattern of mobile lymphocytes (Gowans 1964) ensures 
exposure of a variety of antigen-specific cells to different 
potential sources of antigens. 
Resting Band T lymphocytes are morphologically 
similar, but functionally distinct. Both cell types express 
monoclonal cell surface antigen receptors, and these antigen 
receptors (immunoglobulin (Ig) in B lymphocytes, alP T cell 
antigen receptor (TCR) in T lymphocytes) define the antigen 
specificities of the individual lymphocytes (Klein 1990). 
The B cell antigen receptor, immunoglobulin, recognizes a 
three-dimensional ligand. The alP TCR, on the other hand, 
recognizes short peptides bound to major histocompatibility 
complex (MHC) proteins on the surface of cells. Binding of 
TCR to correct ligand is necessary but not sufficient for 
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functional activation, since T cell activation appears to 
require additional T cell costimulation (Gimmi et ale 1991). 
Two subsets of alP T cells can be defined by the co-
expression of one of the two accessory molecules, CD4 and 
CD8 (Bierer 1989). CD4+ ("helper") T cells make cell-cell 
contact with antigen-presenting cells (APCs) (macrophages, 
activated B cells, and dendritic cells) bearing surface 
peptide-class II MHC (HLA-D in humans) complexes. CD8+ 
("cytotoxic") T cells make cell-cell contact with cells 
bearing surface peptide-class I MHC (HLA-A,B,C in humans) 
complexes. When TCR-peptide-MHC trimolecular complex 
binding, lymphokine levels and co-stimulatory signals are 
sufficient, a lymphocyte becomes activated, expressing 
growth factor receptors, proliferating, secreting 
lymphokines and, in the case of CD8+ cells, destroying 
target cells (Klein 1990). 
The diverse antigen specificities of T lymphocytes are 
defined by their cell surface antigen receptors (Meuer et 
ale 1984; Dembic et ale 1986). A clonal population of 
receptors is found expressed on the lymphocyte surface, and 
single lymphocytes have single antigen specificities. The 
antigen set is both large and unpredictable so, a priori, it 
would seem necessary to generate a highly diverse set of 
antigen specificities in each individual. Single genes 
encoding each of these receptor proteins would quickly 
exhaust the available germline complement of DNA. For both 
Band T lymphocytes, multiple germline gene segments exist 
for different portions of the variable region, and these 
gene segments rearrange in a presumably random fashion to 
form variable region genes prior to transcription. 
Lymphocyte antigen receptor diversity, therefore, accrues 
from germline gene segment repertoire, random junctional 
variation, random combinatorial joining, and combinatorial 
(heterodimeric protein) association (Kronenberg 1986). 
The generation of a diverse set of receptor 
specificities gives the individual the ability to recognize 
and clear pathogens. The spectrum of antigen specificities 
includes self-antigens, allowing the possibility of 
inappropriate self-reactivity. To limit this possibility, 
lymphocytes are selected for absence of self-reactivity 
through mechanisms of tolerance. 
Lymphocyte Tolerance and Self-reactivity 
A random mechanism for generating antigen specificity 
of lymphocyte cell surface receptors offers no means for 
lymphocyte distinction between self and non-self antigens. 
The mechanisms by which self-reactive lymphocytes are 
prevented from causing injury to normal self tissues are 
varied, but collectively referred to as mechanisms of 
"tolerance". Tolerance to self can result from deletion of 
self-reactive clones (von Boehmer 1990) and from induction 
of non-responsiveness in self-reactive clones (Schwartz 
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1990). Deletion can occur in primary lymphoid organs or in 
the periphery, and can occur with both immature and mature 
lymphocytes. T cell unresponsiveness due to anergy 
induction follows inadequate co-stimulation by the antigen-
presenting cell, whereas unresponsiveness can also follow 
from TCR "desensitization" or clonal "exhaustionll (Lo et ale 
1991). B cell unresponsiveness follows inadequate receptor 
occupancy and/or receptor-ligand affinity (Goodnow 1990). 
In summary, both primary and secondary lymphoid organs have 
mechanisms by which lymphocyte self-reactivity can be 
minimized. 
In spite of varied mechanisms of tolerance, mature 
self-reactive lymphocytes can be found in normal individuals 
and lymphoctye-mediated autoimmune diseases are observed 
(Kuby 1992). The rarity of spontaneous autoimmunity 
reflects on the generally effective mechanisms of tolerance 
in normal animals. possible explanations of self-reactivity 
assume an otherwise normal system of tolerance which is 
occasionally misled or "lifted" (Klein 1990). Lymphocytes 
might activate in response to antigens from which the 
maturing set of lymphocytes has been segregated ("antigenic 
sequestration") (Barker 1977). Lymphocytes might activate 
appropriately in response to non-self, but then cross-react 
with self determinants which mimic the non-self determinant 
("molecular mimicryll) (Klein 1990). Lymphocytes might fail 
to activate in response to physiologic concentrations of 
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antigen, but activate in response to supra-physiologic 
concentration of antigen which they encounter acutely 
(Gammon 1989). T lymphocytes might activate in the presence 
of inappropriate co-stimulation by antigen-presenting cells 
(Gimmi et al. 1991). These mechanisms are not due to flaws 
in the mechanisms of tolerance, but rather to untoward side 
effects. 
Risk for T cell autoimmune disease stratifies by MHC 
allele for a variety of diseases in both mice (Fritz 1989) 
and humans (Klein 1990), and key residues in MHC ligand-
binding sites can be identified (Todd et al. 1988). Risk 
for T cell autoimmune disease also stratifies by TCR loci 
RFLPs for a variety of diseases in humans (Posnett 1990). 
The prevention or resolution of autoimmune disease in 
experimental allergic encephalomyelitis (EAE) following 
neonatal thymectomy (Arnason et al. 1962), anti-class II MHC 
antibody (Ab) (Wraith et al. 1989a), anti-TCR Ab (Acha-Orbea 
1989; Zaller 1990), anti-CD4 Ab (Waldor et al. 1985), and 
blocking peptide treatment (Wraith et al. 1989b) suggest 
that these epidemiologic MHC and TCR correlations imply 
causal roles for T cells in pathogenesis. One model is that 
self-peptide binding is necessary but not sufficient for T 
cell self-reactivity, that allelic SUbstitutions within MHC 
ligand-binding sites limit the probabilities of self-
peptides binding to MHC, and that pathogenic trimolecular 
(MHC/self-peptide/TCR) complexes are present in affected 
Definition of the self-peptide epitopes which bind to a 
given MHC allele, definition of the TCR clonotypes which 
recognize these self-peptide/MHC complexes, and development 
of antibody and peptide reagents which interfere with the 
pathogenic trimolecular complex(es) are the obvious long-
term therapeutic goals. 
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At a more basic level, however, the identity of the 
self-protein auto-antigen, the relationships between 
multiple T cell epitopes within the auto-antigen, the rules 
by which disease risk can be predicted from epitope-specific 
responses, the nature of "immunologically privileged" self 
antigen as auto-antigen, and the possibility that TCR V gene 
segment alleles could contribute to disease risk, need to be 
clarified. We have chosen to explore these questions for 
the demyelinating autoimmune diseases, experimental allergic 
encephalomyelitis (EAE) and human multiple sclerosis (MS). 
Similarities of pathologic and clinical features of these 
two diseases suggest that EAE represents a useful animal 
model for the human disease (Alvord 1987). Risk for both 
diseases stratifies by MHC (HLA) haplotype; H-2u mice are 
highly susceptible to induction of EAE (Fritz 1989), and the 
HLA-DR2 allele is over-represented in caucasian humans with 
MS (Veneroni 1988). Activated T cells are found at sites of 
perivascular infiltration and demyelination in both diseases 
(Arnason et ale 1988; Mokhtarian 1984), and adoptive 
transfer of MBP-specific TH cells in mice is sufficient for 
disease induction in mice (Mokhtarian 1984). These data 
suggest that EAE and MS are T cell-mediated autoimmune 
diseases which target components of self central nervous 
system (CNS) myelin. 
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In the EAE model, the best-studied auto-antigen is MBP, 
and synthetic MBP peptides have allowed the identification 
of specific MBP epitopes which stimulate lymphocyte 
activation in different H-2 haplotypes (Kuby 1992). In . 
strains where multiple epitopes exist, certain epitopes 
stimulate more lymphocyte activation following immunization 
with whole MBP than others, and have been called "major 
determinants" or "dominant epitopes". The basis for this 
"epitope dominance" has not been defined. Similarly, most 
mice get disease from these dominant-epitope specific T 
cells, although T cell responses to "subdominant" epitopes 
have been held responsible for a small percentage of 
affected animals in one study (Zaller 1990). For the 
dominant epitope response, the number of responder alP TCR 
clonotypes appears to be limited in number (Acha-Orbea et 
al. 1988), raising the possibility that specific 
immunotherapeutic strategies can be designed. 
Since therapeutic strategies for EAE must consider all 
potentially pathologic trimolecular complexes, it would be 
important to define the number and characteristics of T cell 
epitopes within MBP, to test the ability of epitope-specific 
T cell responses mv~o to predict risk for EAE and, 
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ultimately, to define all of the components of the 
trimolecular complexes which must be targeted. In addition, 
determination of the basis for the breakdown in tolerance 
may offer insight into the limitations on the normal 
mechanisms of tolerance. Chapter 1 of this thesis confirms 
the immunogenicity of self MBP in B10.PL mice, describes the 
immunogenic T cell epitopes of MBP, and defines their class 
II MHC presentation. Chapter 2 determines the effect of 
endogenous MBP expression in BALB/c (H-2 d ) and B10.PL (H-2u ) 
mice on lymphocyte responses to self MBP immunization. In 
MS, risk for disease has been associated with certain TCR V~ 
RFLP haplotypes (Beall 1989; Seboun 1989). The basis for 
this association is unknown, but could be analagous to that 
for the MHC locus, where particular alleles carry an 
intrinsically increased risk for disease. Chapter 3 
describes a comparison of orthologous V~ 8 gene segments 
between different primates, and between unrelated normal 
humans, to define the normal germline variation present in 
V~ gene segments which are adjacent to an MS-associated TCR 
RFLP. 
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Experimental autoimmune encephalomyelitis (EAE') is a T 
cell-mediated autoimmune disease which serves as a good 
model for the demyelinating human autoimmune disease, 
multiple sclerosis. EAE can be induced in susceptible 
individuals by immunization with murine myelin basic protein 
(mMBP) or by adoptive transfer of activated MBP-specific T 
cells. Risk for development of EAE stratifies by H-2 
haplotype, and BI0.PL (H-2U) mice are highly susceptible to 
induction of the disease. The basis for this H-2 
association with EAE disease risk is unknown, but may be 
related to the ability of particular MHC alleles to bind 
processed MBP self-peptides. This study sought to define 
the T cell epitopes within MBP for BIO.PL (H-2 U) mice. 
Following mMBP immunization, T cell proliferative responses 
could be recalled with the component mMBP peptides MBP(NAcl-
20), MBP(31-50) , and MBP(121-140). The bulk of the response 
following mMBP immunization was directed towards the 
MBP(NAcl-20) peptide. Using epitope-specific T cell 
hybridomas and class II transfected L cell lines, it was 
shown thatMBP(NAcl-20) and MBP(121-140) are (I-AU)-
restricted, and that MBP(31-50) is (I-EU)-restricted. This 
confirms the epitope status and class II restriction found 
for NAc(l-20) and (35-47) in another H-2 u mouse strain, 
PL/J, and demonstrates a third epitope for these H-2 u mice. 
Multiple T cell epitopes of varying dominance have been 
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found within self MBP for H-2 u mice, facilitating the study 
of their roles in normal tolerance and inducible 
autoimmunity. 
1 Abbreviations used in this paper: EAE, experimental autoimmune 
(allergic) encephalomyelitis; MBP, myelin basic protein; 
mMBP, murine MBP; MHC, major histocompatibility complex; 




The mammalian response to most pathogens relies on the 
specific immune response of lymphocytes, and this response 
hinges on the abilities of Band T lymphocytes to 
distinguish self from non-self (Goodnow 1990; von Boehmer 
1990). This distinction is occasionally unclear, as mice 
and humans both develop diseases in which the targets of the 
specific immune response are self proteins (Klein 1990; Kuby 
1992). Risk for some of these diseases stratifies by MHC 
allele (Klein 1990) or by TCR loci RFLPs (Posnett 1990), 
suggesting that particular MHC/TCR/self peptide complexes 
may play a role in the pathogenesis of these autoimmune 
diseases. 
The molecular basis for autoimmune pathogenesis can 
best be studied in a defined model system. Experimental 
autoimmune encephalomyelitis (EAE) is considered a good 
model of the human demyelinating disease, multiple sclerosis 
(MS) (Alvord 1987; Zamvil 1990). In both cases, risk for 
disease stratifies by MHC (HLA) allele (Fritz 1989; Veneroni 
1988), and both clinical and pathologic features are 
comparable (Mokhtarian 1984; Arnason 1988). In EAE, the 
components of the disease-associated trimolecular complex 
(MHC, TCR, and peptide) have been defined for a variety of 
H-2 haplotypes (Zamvil 1990). strains which are susceptible 
to EAE (e.g., B10.PL (H-2 u» (Fritz 1989) respond well to 
immunization with purified MBP, whereas those which are not 
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susceptible to EAE (e.g., BALBjc (H-2 d » do not respond well 
to immunization with purified MBP. Overlapping MBP peptides 
can be used to restimulate T lymphocytes initially activated 
following mMBP immunization. These peptides estimate, and 
allow mapping of, the actual (unknown) T cell epitopes of 
MBP. The predominant in vitro T cell response is found to be 
directed towards the epitope within MBP(NAc1-20), and this 
response is used by the majority of affected animals (Acha-
Orbea 1988; Zaller 1989). Adoptive transfer of EAE with 
dominant epitope-specific T cell clones (Zamvil 1985), and 
reversal of EAE by using monoclonal antibodies to deplete 
the animal of dominant epitope-specific T cells (Acha-Orbea 
1988; Zaller 1990), suggests that these epitopes and their 
trimolecular complexes are in fact pathogenic. 
Although the dominant epitope predicted the pathology 
in the majority of animals in one study (Zaller 1990), one 
animal in twenty remained ill, and this was attributed to a 
T cell response directed towards the subdominant epitope, 
MBP(121-140). The epitopes involved in pathogenesis may 
therefore include subdominant as well as dominant epitopes. 
It is clear that the number of epitopes and the nature of 
the T cell responses to them is important in devising 
therapies designed to delete or tolerize small portions of 
the peripheral T cell repertoire. 
The goal of this study was to define the number, 
characteristics, and restriction elements of the T cell 
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epitopes of MBP recognized in the EAE-susceptible H-2u mouse 
strain, B10.PL (H-2 U). Five peptides (MBP(NAcl-20), MBP(31-
50), MBP(101-120), MBP(121-140), and MBP(131-150» were 
individually immunogenic, three of these (MBP(NAcl-20), 
MBP(31-50), and MBP(121-140» could recall a proliferative 
response in lymph node cells following self (murine) MBP 
immunization, and MBP(NAcl-20) predominated in the 
proliferative response. The two adjacent peptides, MBP(121-
140) and MBP(131-150), shared a single epitope. The T cell 
epitopes of MBP, defined from responses following MBP 
immunization, were also found to be encephalitogenic. The 
dominant epitope response predicted the highest probability 
for disease induction. MBP(101-120) was incapable of 
recalling a proliferative response following mMBP 
immunization, and was also found to be non-encephalitogenic. 
MBP(NAcl-20) and MBP(121-140) were found to be presented by 
class II I-Au, and MBP(31-50) was found to be presented by 
class II I-Eu. Given knowledge of the auto-antigen and its 
amino acid sequence, derived epitope maps for disease-
susceptible MHC or HLA haplotypes may allow prediction, and 
possibly prevention, of the pathologic trimolecular complex 
interactions which characterize T cell-mediated autoimmune 
diseases. 
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III. Materials and Methods 
Mice 
B10.PL mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME) or derived from Jackson mating pairs at 
Cal tech. Immunization and disease induction experiments 
utilized 6-10 week old animals. 
Myelin Basic Protein (MBP) 
Murine MBP was prepared from frozen mouse brains (Pel-
Freeze Biologicals Co., Rogers, AR) according to a 
previously published protocol (smith 1969). 
Peptides 
Peptides were synthesized by the stepwise solid-phase 
technique (Sluka 1990). The numbering scheme is based on 
the amino acid sequence of the 18.5 kD form of MBP, an 
isoform translated from a transcript of exons I, III, IV, V, 
VI, and VII of the MBP gene (deFerra 1985) (Table 1). 
Mouse MBP Immunization Regimen 
Murine MBP or MBP peptides were emulsified with an 
equal volume of complete Freund's adjuvant (CFA, Gibco 
Laboratories, Grand Island, NY) supplemented with 4 mg/ml M. 
tuberculosis H37 RA (Difco Laboratories, Detroit, MI). Mice 
were immunized with a total of 55 - 75 ~g MBP, or 50 - 100 
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nmoles of MBP peptide, in equal 50 ~l volumes SC in the hind 
footpads. For disease induction, mice were also given 
pertussigen 75-250 ng IV at 24 and 72 h after immunization. 
EAE Disease Severity 
Clinical EAE was graded on a 5 point scale: grade 1, 
flaccid tail; grade 2, hind limb weakness; grade 3, hind 
limb paralysis; grade 4, fore/hind limb paralysis; grade 5, 
death. 
In vitro lymph node cell proliferation assay 
Mice were sacrificed by cervical dislocation ten days 
after immunization. Inguinal and popliteal lymph nodes were 
sharply dissected and excised, and were suspended in ventrex 
HL-l serum free medium (Ventrex Laboratories, Portland, ME) 
or complete RPMI (for the (81-100) immunization experiment) 
after crush dissociation. Viable lymph node cells were then 
plated at 3 - 4 x 10'lwell in 200-250 microliter/well in 
Falcon 3077 96 well round bottom plates (Becton Dickinson & 
Co., Lincoln Park, NJ), and murine MBP (mMBP) (from the same 
preparation as that used in the immunization) or HPLC-
purified synthetic peptides were added. Four days later, 1 
uCi [methyl-3H] thymidine was added to each well and cells 
were collected 16-24 hours later on Whatman 934-AH glass 
fiber filters (Whatman Co., Maidstone, England) using a PHD 
cell harvester (Cambridge Technology, Inc., Cambridge, MA). 
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Counts per minute (CPM) from triplicate wells were 
determined by liquid scintillation counting, and calculated 
disintegrations per minute (DPM) were used for analysis 
where noted. 
Class II MHC transfectants 
The I-Au L cell transfectant, 6A2, was a generous gift 
from Dr. Pat Jones. I-Au expression is HAT-selected. The 
I-Eu L cell transfectant, 40, was a generous gift from Dr. 
Ginnie Appel. I-Eu expression is G418-selected. Cells were 
grown in complete aMEM (FCS (10%), glutamine (2 roM), and 
penicillin (100 U/mL)/streptomycin (100~g/mL), caMEM with 1x 
HAT (50X = hypoxanthine 5 x 10-3 M, aminopterin 2 x 10-5 M, 
and thymidine 8 x 10~ M), or in caMEM with G418 (400~g/mL). 
MHC-specific monoclonal antibodies 
MoAb Y-3P (ATCC HB 183) binds to H-2 I-Au molecules. 
MoAb 14-4-4S (ATCC HB 32) binds to H-2 I-Eu molecules. MoAb 
30-5-7 binds to H-2 d class I molecules. MoAb 11-4.1 (ATCC 
TIB 95) binds to H-2 ~ molecules. 
FACS Analysis 
The above antibodies were used as cell culture 
supernatants to stain ca. 1 x 106 cells/sample, on ice, for 
30-45 minutes. Free antibody was washed off, and FITC-GAM 
secondary Ab was used to detect bound primary Ab. 
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IV. Results 
Immunogenicity of murine myelin basic protein (mMBP) 
To rule out the possibility that the observed responses 
to mMBP and/or mMBP peptides were due to cross-reactivity 
with adjuvant components, BI0.PL mice immunized with 
Freund's adjuvant (ICFA), Freund's adjuvant with ~ 
tuberculosis (CFA), or murine MBP in Freund's adjuvant with 
M. tuberculosis (mMBP/CFA), were compared. As shown in 
Figure 1, mice immunized with ICFA failed to respond to 
restimulation with mMBP, mMBP peptides, or PPD ("Mtb", 
tuberculin). Mice immunized with CFA responded to 
restimulation with PPD, but did not respond to restimulation 
with mMBP or mMBP peptides. Mice immunized with mMBP/CFA, 
however, responded to restimulation with mMBP, mMBP 
peptides, and PPD, demonstrating that there is no false 
positivity from cross-reactivity associated with the 
observed responses to peptide stimulation in vitro. 
Immunogenic peptides in BlO.PL mice 
To determine the T cell proliferative response to all 
of the MBP peptides, two sets of peptides, each representing 
one half of the total MBP length, were separately pooled and 
used to immunize 3 - 4 naive BI0.PL mice. As shown in 
Figure 2, significant (stimulation index> 3) activation of 
BI0.PL lymph node cells resulted from re-stimulation with 
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peptides NAc(I-20), (31-50), (101-120), (121-140), and (131-
150). These results do not rule out the possibility that 
some peptides failed to stimulate T cells because of 
competition for presentation. 
Response to Murine Myelin Basic Protein (mMBP) in BIO.PL Mice 
To determine the response of BI0.PL mice to the intact 
self protein, mMBP, purified MBP emulsified in CFA/M.Tb. was 
used to immunize 28 naive BI0.PL mice. Lymph node cells 
from these animals were compared for responsiveness to all 
of the individual mMBP peptides (n=16), mMBP (n=26), NAc(l-
20) (n=28), and (31-50) (n=28). Figure 3 illustrates the 
fraction of mice in the sample able to respond above 
background (P<0.05) and (P<O.OI) to peptide stimulation in 
vitro following mMBP immunization, and shows that B10.PL 
mice can respond to 4 - 5 different epitopes within the 18.5 
kD mMBP molecule. Averaged in vitro lymph node proliferation 
(incorporated ~-TdR DPM) is given in Table 2 for the 
individual mice studied. Averages of the net DPM responses 
to individual mMBP peptides are illustrated in Figure 4, and 
demonstrate that B10.PL mice respond predominately to 
MBP(NAcl-20), with significant (P<O.Ol) responses to MBP(31-
50) and MBP(121-140). The immunogenicity of peptide 
MBP(101-120) shown in Figure 2 contrasts with the absence of 
response to (101-120) following mMBP immunization, and 
suggests that this epitope is cryptic in vivo, i.e., not 
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presented by antigen-presenting cells to peripheral T cells. 
H-? presentation of MBP(NAc1-20) 
To define the response to restimulation with MBP(NAcl-
20) as being T cell-mediated, BIO.PL (H-2 U ) and BIO.T(6R) 
(H-2q ) mice were compared for responsiveness to mMBP 
immunization. These mice are near-isogenic save for the H-2 
locus, so their antigen processing and germline TCR/Ig 
repertoires should be identical. As shown in Figure 5, 
BIO.T(6R) mouse lymph node cells fail to be restimulated by 
MBP(NAcl-20), suggesting the observed proliferative response 
is a function of the ability of H-2 u MHC molecules to 
present MBP(NAcl-20) . 
Peptides (121-140) and (131-150) contain a single T cell epitope 
To clarify the apparent responsiveness of BIO.PL mice 
to the two adjacent peptides, MBP(121-140) and MBP(131-150), 
mice were immunized with each peptide and restimulated in 
vitro with both peptides individually. As shown in Table 3, 
T cells specific for MBP(121-140) or MBP(131-150) cross-
react with the adjacent peptide, suggesting that a single T 
cell epitope is shared by these two peptides. 
Incidence of EAE after Peptide Immunization 
The incidence, time of onset, and severity of clinical 
EAE following immunization with individual mMBP peptides in 
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adjuvants are shown in Table 4. BI0.PL mice routinely got 
(severe) EAE after MBP(NAcl-20) immunization, occasionally 
got (less severe) EAE after MBP(31-50) and MBP(121-140) 
immunization, and failed to get EAE after MBP(101-120) 
immunization. These outcomes parallel the observations made 
on mv~o restimulation with these peptides following mMBP 
immunization, and suggests that self MBP processing and 
presentation of an epitope mimicked by the peptide is 
required for the peptide to be an effective encephalitogen. 
Class II Restriction 
The MHC class II (-) L cell line, L929, the class II 1-
AU L929 transfectant "6A2", and the class II I-Eu L929 
transfectant "4D" , were used as antigen-presenting cells for 
determination of the class II restricting elements for the 
peptides NAc(1-20), (31-50), and (121-140). Figure 6 shows 
that L929 is class II (-), that 6A2 expresses I-Au (detected 
with the MoAb Y3P), and that 4D expresses I-Eu (detected 
with the MoAb 14-4-4). Figure 7 shows that MBP(NAcl-20) is 
presented by 6A2 (I-AU), that MBP(31-50) is presented by 4D 
(I-EU), and that MBP(121-140) is presented by 6A2 (I-AU). 
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V. Discussion 
MBP as an immunogenic protein • 
The T cell autoimmune response has been attributed to 
cross-reactivity with microbial pathogens in both EAE 
(Fujinami 1985) and experimental autoimmune uveitis (EAU) 
(Sing 1989). Data in this paper shows that the observed 
response to MBP is not due to a cross-reactivity with 
components of Freund's adjuvant or M. tuberculosis. This 
suggests that T cells are not tolerized to MBP, rather than 
being (inappropriately) cross-reactive to MBP following a 
xenoprotein response. B10.PL mice are therefore not 
tolerized to MBP, and the basis for this (e.g., antigenic 
sequestration, epitope-specific tolerance, incomplete 
tolerance, dose-specific tolerance) is unknown. 
MBP as a multiple-epitope immunogenic protein. 
Synthetic peptides were used in this report to document 
the number and characteristics of the epitopes within the 
self-protein, MBP. MBP(101-120) is immunogenic, but fails 
to recall a response following mMBP immunization and fails 
to trigger EAE. This implies that MBP(101-120) binds to 
self MHC class II molecules, that MBP(101-120)-specific T 
cells exist, and that these T cells can expand in response 
to synthetic peptide on H-2 u APCs. They do not expand, 
however, in response to processed and presented MBP, and 
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this suggests that the peptide epitope estimated by MBP(101-
120) is altered during MBP processing by APCs, or fails to 
compete successfully for presentation by surface MHC class 
II molecules. 
MBP(NAc1-20), MBP(31-50) and MBP(121-140) are 
immunogenic peptides, recall proliferative responses 
following mMBP immunization, and trigger EAE. This implies 
that they bind to self MHC molecules, that they are a good 
estimate of the actual peptide epitopes resulting from 
processing of MBP by APCs, and that T cells exist which can 
expand in response to APCs presenting these peptides. 
In B10.PL mice, T cells can recognize five MBP-derived 
peptides, APC processing provides peptides similar to three 
of these, and one of these three (MBP(NAc1-20» dominates as 
a target for the response to mMBP immunization. 
Class II MHC presentation of mMBP epitopes. 
Our data suggest that the epitope estimated by 
MBP(NAc1-20) is presented to T cells by the I-Au class II 
MHC molecule, and that the epitope estimated by MBP(31-50) 
is presented to T cells by the I-Eu class II MHC molecule. 
These observations are consistent with the class II 
restriction element data on MBP epitopes in PL/J, another H-
2u strain (Zamvil 1990). In addition, we have determined 
that MBP(121-140) is presented to T cells by the I-Au class 
II MHC molecule. Since MBP(NAc1-20) and MBP(121-140) are 
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both presented by I-Au, this may offer a model to study the 
factors involved in T cell activation and tolerance to 
epitopes of a well-defined self protein. 
Basis for subdominance of epitopes. 
The basis for the reduced proliferative responses to 
some synthetic MBP peptides following mMBP immunization is 
unknown. We have shown that the immunogenicity of MBP, 
rather than that of other antigens present in the adjuvants, 
is responsible for the proliferative responses recalled by 
synthetic peptides following mMBP immunization. We have 
shown that pooled peptide immunization results in comparable 
proliferative responses upon in vitro restimulation with 
individual peptides within the pool (Table 2). This 
suggests that competitive inhibition by MBP(NAcl-20) does 
not account for the subdominant response to MBP(31-5b) 
following mMBP immunization, and that competitive inhibition 
by MBP(121-140) does not account for the absent response to 
MBP(lOl-120) following mMBP immunization. Additional 
experiments (data not shown) have failed to demonstrate 
competitive inhibition by MBP(NAcl-20) for presentation of 
MBP(121-140) by I-Au, have failed to demonstrate cross-
reactivity between epitopes MBP(NAcl-20), MBP(31-50), and 
MBP(121-140), and have failed to demonstrate substantially 
increased responses for MBP(31-50) by varying the length and 
frame of the peptide. These data suggest that subdominance 
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is due not to the absence of specific T cells, but rather to 
the inability of APCs to generate adequate densities of 
surface (class II MHC - peptide) complexes. The 
subdominance of MBP(31-50) is particularly prominent, given 
its immunogenicity as a peptide, suggesting abnormalities of 
MBP processing. 
Risk for EAE is correlated with epitope dominance 
The prevalence and severity of EAE following 
immunization with peptides in adjuvants is roughly 
correlated with the proportion of the proliferative response 
attributed to each peptide following mMBP immunization, 
i.e., most mice get EAE after MBP(NAc1-20) immunization, and 
fewer get EAE after immunization with MBP(31-50) or MBP(121-
140) (Table 5). The proliferative response appears to 
predict the risk for disease, but subdominant (lower-level) 
responses do not rule out risk for disease. No disease 
resulted following immunization with MBP(lOl-120) , the 
peptide which was immunogenic but not presented following 
immunization with intact mMBP. This is consistent with a 
model in which presentation of processed self MBP peptide is 
necessary, but not sufficient, for disease induction and 
progression. This emphasizes the need for determination of 
the antigen and its component epitopes in the study of 
autoimmune diseases. 
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Text references to these peptides are given as 
"MBP (peptide) ". "NAcl-20" refers to the N-acetylated 
derivative of the amino-terminal 20-mer. This numbering 
system does not take the exon 2-encoded amino acid residues 
(n=26) into account. Peptide (104-113)/(155-164) ("E6(-» 
is an (exon 5, exon 7)-encoded fusion peptide made to mimic 
the 14 kD MBP isoform (E6(-» protein sequence. 
Table 2: 
B10.PL (H-2u ) mice were immunized with 75-200 ~g mMBP 
in CFA. Lymph nodes were harvested 10 days later, and 3-4 x 
105 viable cells/well were incubated with murine MBP for 5 
days. One ~Ci 3H- TdR was added during the last day, cells 
were filtered, and CPM were counted. Data points reflect 
the mean of triplicate samples, and are given as mean DPMs 
(3H- TdR) for each peptide (30. ~M) or (-) antigen control. 
Three of these animals were tested at both 3. and 30. ~M 
[peptide]; for these mice, the larger of the two 
proliferative responses are listed. The wilcoxson signed 
rank test and Student's paired T test were used to determine 
statistically significant differences of peptide-stimulated 
samples from paired background control samples, as depicted 
in Figure 4. 
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Table 3: 
B10.PL response to immunization with MBP(121-140)/CFA 
or MBP(131-150)/CFA. Lymph node cell in vitro proliferation assays 
were performed as described in Table 2. Proliferation in 
response to 30. ~M peptide (immunogen or adjacent 
overlapping peptide) was estimated by net DPM (~-TdR) above 
(-) antigen (medium only) background control. 
Table 4: 
B10.PL mice were immunized with 50-100 nmoles SC of 
peptide in CFA. Pertussigen 75-400 ng IV was given 24 and 
72 hours after immunization. Incidence indicates the 
proportion of mice which developed detectable signs of EAE. 
Onset indicates the average day of first signs of EAE, with 
the associated sample range. severity indicates the 
average maximal grade of disease observed in each sample. 
Tab1e 1. OVer1appinq Peptides fro. the 18.5 kD Form of 
Hurine Hye1in Basic Protein 
Peptide Name Peptide Sequence Coded by Exon 
NAc1-20 ASQKRPSQRSKYLATASTMD I 
11-34 KYLATASTMDHARHGFLPRHRDTG I 
22-40 ARHGFLPRHRDTGILDSIG I 
31-50 RDTGILDSIGRFFSGDRGAP I 
41-58 RFFSGDRGAPKRGSGKDS I, III 
49-70 APKRGSGKDSHTRTTHYGSLPQ I, III 
61-80 RTTHYGSLPQKSQHGRTQDE III 
68-91 LPQKSQHGRTQDENPVVHFFKNIV III, IV 
81-100 NPVVHFFKNIVTPRTPPPSQ III, IV 
87-114 FKNIVTPRTPPPSQGKGRGLSLSRFSWG III, IV, 
40 
V 
101-120 GKGRGLSLSRFSWGAEGQKP IV, V, VI 
111-130 FSWGAEGQKPGFGYGGRASD V, VI 
121-140 GFGYGGRASDYKSABKGFKG VI 
131-150 YKSABKGFKGAYDAQGTLSK VI 
141-160 AYDAQGTLSKIFKLGGRDSR VI, VII 
151-168 IFKLGGRDSRSGSPMARR VI, VII 
104-113/ RGLSLSRFSWGGRDSRSGSP V, VII 
155-164 
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Table 2: B10.Pl (H·ZU) lymph Node Cell Proliferative Responses 
Following mMBP Immunization 
Animal # {-} Ag mMBP NAc{1-20} {"-34} {22-40} Pl-50} {41-58} {49-70} {61-80} (68-91) 
1 6651 NT 26495 10093 9388 9741 7035 11180 8375 9014 
2 9451 NT 29832 29832 29832 29832 29832 29832 29832 29832 
3 11047 39933 69073 8077 8817 21468 5395 4096 6974 9515 
4 6035 26171 34699 18771 6820 14357 5594 4839 4077 7920 
5 7951 36524 63586 10355 11203 14151 5984 21369 14782 17859 
6 4535 23268 43062 4337 4378 14762 4780 6225 2692 10522 
7 3805 13920 11646 3926 3553 3618 3783 2470 3534 11062 
8 4835 22631 23049 6341 6706 4809 6271 4573 6277 11358 
9 3849 12736 17292 5113 4784 3278 5495 3834 3655 17108 
10 11160 59907 56036 10379 13851 13213 14841 12358 13432 36341 
11 4913 36890 71892 7514 4455 4453 7950 6896 6132 6921 
12 10844 54661 108910 12125 12953 10519 29901 11099 10871 13706 
13 5494 55128 94815 5044 6286 6806 10442 4560 7827 8859 
14 3404 NT 41443 1123 785 1055 1175 887 767 700 
15 3191 NT 51147 7384 2857 2823 4474 3421 2682 3806 
16 12188 , NT 69743 16297 18070 14165 6690 7603 11230 9193 
20 2876 10420 17964 6357 
21 1760 3252 8523 3214 
22 1999 8433 12514 4236 
23 3043 14971 57900 5113 
24 2085 4286 36196 4752 
25 1227 1212 5603 2833 
26 1563 1348 28895 5878 
27 1733 1649 17610 5222 
28 2319 15699 93898 19842 
29 1480 2198 45861 4912 
30 no 1256 4354 811 
31 2475 1831 26668 n38 
Animal # {-l A9 {81-100l {87-114l ~101-120l~111-130l~121-140l(131-150l~141-16Ol{151-168l E6{-l 
1 6651 16004 6640 13897 8529 11853 11716 12234 12825 8516 
2 9451 29832 29832 29832 29832 29832 29832 29832 29832 11182 
3 11047 9813 2332 8967 6342 14375 7047 3791 7505 9087 
4 6035 8636 2507 11148 5137 15885 7841 4438 9448 5117 
5 7951 20506 11885 10213 7135 20879 13070 8158 12680 11028 
6 4535 7n9 2980 13339 7667 8265 6786 3113 7398 9715 
7 3805 3849 1697 2489 3674 4087 5806 3435 1937 2865 
8 4835 5041 4296 51n 4686 6712 14311 12585 13829 10334 
9 3849 3947 4126 5261 6096 4732 14291 17158 14126 10119 
10 11160 12461 10085 12701 12722 12119 13917 11648 12674 11680 
11 4913 6863 3756 5154 3939 14442 9857 6611 8228 13105 
12 10844 11924 10360 14813 9482 32084 17024 8590 18686 16327 
13 5494 8579 4822 5111 6734 15313 9200 6717 7694 6780 
14 3404 887 NT NT NT NT NT NT NT NT 
15 3191 4509 NT NT NT NT NT NT NT NT 
16 5909 11602 NT NT NT NT NT NT NT NT 
17 2652 41n 3382 7006 3519 2961 4949 3992 6282 NT 
18 2308 1378 1003 2493 1517 2615 11480 1800 3915 NT 
19 1m 2491 1737 1803 1117 2896 5801 1680 5108 NT 
20 2876 2068 
21 1760 2129 
22 1999 2134 
23 3043 1457 
24 2085 7431 
25 1227 8723 
26 1563 2020 
27 1733 988 


































































































































































































































































































































































































Responses of B10.PL mice to immunization with 
incomplete Freund's adjuvant, complete Freund's adjuvant 
with M. tuberculosis (CFA), or murine MBP (75. ~g) in CFA. 
Mice were immunized SC in the hind footpads with 100.~L of 
each emulsion. Lymph nodes were harvested 10 days later, 
and 3-4 x 105 'viable cells/well were incubated with murine 
MBP, individual overlapping MBP peptides (30 ~M each), or 
PPD for for 5 days. One ~Ci ~-TdR was added during the 
last day, cells were filtered, and CPM were counted. Data 
points reflect the mean of triplicate samples, and error 




Response of B10.PL mice to immunization with pools of 
synthetic peptide. six mice were immunized with a pool of 8 
or 9 peptides containing 20. nmoles of each peptide, 
components of the two pools shown in the abscissas of the 
upper and lower histograms. In vitro proliferative responses 
upon restimulation of lymph node cells (see Figure 1 legend) 
with each of the peptides (30. ~M) individually are given as 
net DPM (3H- TdR). 
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Figure 3. 
Proportion of Bl0.PL mice which demonstrate 
statistically significant proliferation to mMBP or mMBP 
peptide stimulation following mMBPjCFA immunization. 
Proliferative responses to stimulation with each MBP peptide 
for each mouse listed in Table 2 were compared statistically 
(unpaired Student's T test) to (-) antigen background 
control samples. Increased proliferation was noted by 
significance ievel, and proportion of mice responding to 
each peptide at P<O.OS and P<O.Ol significance were 
tabulated. 
Figure 4. 
Response of Bl0.PL mice to immunization with mMBPjCFA. 
The proliferative responses listed in Table 2 were compared 
(using both the paired Student's T test and the wilcoxson 
signed rank test) to determine statistically significant 
difference from background for mMBP and each mMBP peptide. 
The mean and standard error of the mean are shown, and 
peptides which re-stimulate significantly above background 
are shown for P<O.OS and P<O.Ol significance levels. 
Figure 5. 
Response of Bl0.PL and BIO.T(6R) mice to immunization 
with mMBPjCFA. Mice immunized with 75. ~g mMBPjCFA and 
assayed as in the Figure 1 legend. This antigen dose-
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proliferative response curve indicates the mean and standard 
error of the difference of the means for triplicate samples, 
and each curve represents the response of one mouse. 
Figure 6. 
L cell transfectant expression of I-Au or I-Eu. L929 
(class II (-», 6A2 (I-AU (+», and 40 (I-EU (+» were 
stained on ice with cell supernatant MoAhs 30-5-7 
(irrelevant control), 11-4-1 (class I (+) control), Y3P (1-
AU-specific), or 14-4-4 (I-EU-specific). Antibody binding 
was detected with FITC-conjugated goat anti-mouse secondary 
antibody, and fluorescence per cell is indicated on a linear 
scale. 
Figure 7. 
L cell transfectant presentation of MBP peptides to 
MBP-specific T cell hybridomas. L cell transfectants 
(105/well) 6A2 (I-AU (+» or 40 (I-EU (+» were mixed with T 
hybridomas (105/well) specific for MBP(NAcl-20) (172.10), 
MBP(31-50) (122.13), or MBP(121-140) (B27.1), and the net 
IL2 release in response to increasing concentrations of 
cognate ligand was measured. Bar height indicates the mean 
for triplicate samples, and error bars indicate the standard 
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I. Summary 
The immune system is generally tolerant to self proteins. 
The breakdown of self-tolerance can lead to autoimmune 
diseases such as multiple sclerosis, insulin-dependent 
diabetes mellitus, and rheumatoid arthritis. Experimental 
allergic encephalomyelitis (EAE) 1 is considered a good 
animal model for the human demyelinating disease, multiple 
sclerosis. EAE can be induced by immunization with myelin 
basic protein (MBP) in adjuvants and by adoptive transfer of 
MBP-specific CD4+ T lymphocytes. Inbred strains of mice 
with different H-2 haplotypes vary in their responsiveness 
to immunization with MBP and in their susceptibilities to 
EAE. For example, H-2d strains are tolerant to MBP, but H-
2u strains develop EAE upon immunization with MBP. The 
basis for the correlation of MHC haplotype with risk for EAE 
is unknown, but may be related to the ability of MBP~derived 
peptides to bind to specific MHC class II molecules. In 
this study, mouse MBP-specific lymph node proliferative 
responses of normal and MBP-deficient "shiverer" mice were 
compared. H-2d shiverer mice were hyper-responsive to both 
intact MBP and peptide MBP(81-100) compared to non-shiverer 
littermates. H-2u shiverer mice were hyper-responsive to 
both intact MBP and peptide MBP(121-140) compared to non-
shiverer littermates. We conclude that MBP is not a 
sequestered self antigen, since its expression induces 
tolerance to specific T cell epitopes in wildtype H-2d and 
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H-2 U mice. H-2u wildtype and shiverer littermates were 
equally responsive to peptides MBP(NAcl-20) and MBP(31-50). 
Thus, tolerance to MBP in H-2u mice appears to be epitope-
specific. Residual lymph node cell responses to MBP(81-100) 
in normal H-2d mice, and to MBP(121-140) in normal H-2u 
mice, indicate that this tolerance is incomplete. 
Incomplete tolerance to peripheral self antigens may account 
for the presence of autoreactive cells in adult mice. 
1 Abbreviations used in this paper: EAE, experimental allergic 
encephalomyelitis; MBP, myelin basic protein; mMBP, murine 
MBP; OLA, oligonucleotide ligation assay; HEL, hen egg 
lysozyme; NAc-, N-acetyl. 
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II. Introduction 
T cells can rearrange their TCR a/~ loci in a highly 
diverse fashion (1,2), generating a set of T cell 
specificities which includes reactivities to self proteins 
(3). In adult mice, however, spontaneous T cell self-
reactivity is unusual (4), so mice are generally self-
tolerant. Tolerance of mature T cells to self antigens may 
result from one of several mechanisms, including thymic 
deletion of self-reactive immature T cells (5,6), peripheral 
inactivation (anergy) of self-reactive mature T cells 
(7,8,9), peripheral deletion of self-reactive mature T cells 
(10), and conceivably from active suppression of self-
reactive mature T cells by CD8(+) regulatory cells (11). 
T cell tolerance to self antigens occasionally fails, 
as evidenced by a variety of human (12) and murine (13) 
autoimmune diseases. A number of mechanisms for this 
breakdown in tolerance have been postulated. T cells might 
come into contact with sequestered self antigens to which 
they have never become tolerant (14). T cells might 
activate in response to a foreign antigen and then cross-
react with a self antigen which mimics the nonself T cell 
epitope (15). T cells which are tolerant to low levels of 
antigen might activate in response to higher levels (16). 
Finally, inappropriate costimulation by antigen-presenting 
cells (APCs) might lead to inappropriate T cell activation, 
rather than anergy, upon antigen contact (17,18). 
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Mature T cells recognize a ligand comprised of short 
peptides bound to self MHC surface proteins. Class I MHC 
molecules present 8-9 residue peptides (19) processed from 
cytoplasmic proteins (20). Class II MHC molecules present 
13-17 residue peptides (21) processed from endocytosed 
proteins (22). Self proteins are apparently processed and 
presented by APCs in the same ways as non-self proteins 
(23). A processed self peptide derived from hemoglobin can 
be found on the surface of antigen-presenting cells (APCs) 
of most tissues (24), suggesting that T cell self-tolerance 
is due to an absence of T cell responsiveness rather than to 
self/non-self discrimination at the level of APe function. 
A good model for studying the cellular and molecular 
processes of self-tolerance would be one in which the 
components of the TCR/MHC/self-peptide trimolecular complex 
have been well-defined, in which T cells recognize multiple 
epitopes within the same self protein, and in which the 
level of the tolerizing self protein can be varied. The T 
cell response to myelin basic protein (MBP) represents such 
a model. The role of MBP as a target self antigen in the T 
cell-mediated autoimmune disease, EAE, is well-documented 
(25). Proteolytic processing of MBP is required for T cell 
activation (26), and multiple epitopes are recognized by 
some strains of mice (15). MBP expression is limited to the 
nervous system, comprising 30-40% of CNS myelin and 5-15% of 
PNS myelin (27). Expression of the ~p gene varies 
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naturally due to two alleles, wildtype (+) and shiverer 
(shi) (27, 28,29). The wildtype allele of Mbp (Mbp+) has seven 
exons (30, 31), of which the last five exons are deleted in 
the shi allele (mb~) (32, 33). Although the MBP gene is 
largely deleted in the shi allele, the remaining exons 1 and 
2 are transcribed (34). However, they do not appear to be 
translated, since no protein is detected (27,28,29). Mice 
that are homozygous for the shi allele (shiverer, mb~ mice) 
are therefore considered MBP nUll. These animals have a 
hypomyelinated eNS, motor tremors, tonic seizures, and a 
shortened lifespan (27). 
In this study, T cell responses to MBP immunization in 
shiverer and non-shiverer mice of H-2d and H-2u haplotypes 
were compared. Enhanced strain-specific responsiveness to 
certain epitopes of MBP was observed in shiverer mice. MBP 
is therefore not sequestered from the immune system, . since 
its expression in normal mice leads to partial tolerance. 
Epitope-specific tolerance was suggested by comparison of 
responses to mMBP-derived peptides in H-2 u shiverer and non-
shiverer mice. MBP represents a good model for the study of 
tolerance to a self protein which is etiologic to a well-
defined autoimmune disease. 
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III. Materials and Methods 
Shiverer mouse breeding 
Outbred shiverer mice were crossed with BALB/c mice, 
progeny intercrossed, and shiverer offspring backcrossed 
with BALB/c mice. The mice used in the experiment were from 
the 12th backcross (generous gift of Dr. Richard L. Sidman). 
Outbred shiverer mice were crossed with B10.PL mice, 
progeny intercrossed, and shiverer offspring backcrossed 
with B10.PL mice. The mice used in the experiments were the 
offspring from intercrosses following the first or second 
backcrosses. First intercross offspring were screened for 
H-2 haplotype (see below), and only H_2U!U mice were studied. 
Mice were maintained in a clean, non-sterile environment 
during the period before and after immunization. 
Shiverer mice are homozygous for the shiverer allele of 
the gene encoding MBP. We propose to identify this gene as 
~p, the alleles of this gene as ~p+ and mbpw, and the 
genotypes of the mice as ~p+ (homozygous, normal 
phenotype), ~p+/mbpn (heterozygous, normal phenotype), and 
mbpn (homozygous, shiverer phenotype). 
Mouse MBP purification 
Murine MBP was prepared from frozen mouse brains (Pel-
Freeze Biologicals Co., Rogers, AR) according to a 
previously published protocol (35). 
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Peptide synthesis 
Peptides were synthesized by the stepwise solid-phase 
technique (36). The numbering scheme is based on the amino 
acid sequence of the 18.5 kD form of MBP, an isoform 
translated from a transcript of exons I, III, IV, V, VI, and 
VII of the MBP gene (31) (Table 1). 
MHC screening with the Oligo Ligation Assay (OLA) 
For experiments involving intercross offspring from 
first generation backcross matings of outbred shiverer mice 
(H_2unknown) with B10. PL (H-2u) mice, DNA polymorphisms within 
coding sequences for class II I-A proteins were used to 
distinguish H-2u and H_2~known mice. The region containing 
the polymorphism was PCR-amplified using oligos (5'- TATCA 
GTCTC CTGGA GACAT TGGCC -3') and (5'- GGTAG CTGGG GTGGA 
ATTTG ACCTC -3'). The oligo ligation assay (OLA) (37,38) 
used the oligos (5'- AAAAC ACAAC TTGGG A -3') (common to all 
alleles) and (5'- TGCAA AACAT AGCTA CAGG -3') (I-Au-
specific) to determine the presence of the I-Au allele. 
MBP allele screening with polymerase chain reaction (PCR) 
Phenotypically, MBpM+ mice are indistinguishable from 
wildtype mice. Normal littermates were screened for the 
presence of the shiverer MBP allele using oligonucleotide 
primer pairs flanking the ~i allele deletion site (33) (5'-
CAGGG GATGG GGAGT CAGAA GTGAG -3',5'-ATGTA TGTGT GTGTG TGCTT 
ATCTA GTGTA -3') were synthesized and used for PCR 
amplification (39). PCR product indicated the presence of 
the shi MBP allele. 
Mouse MBP immunization regimen 
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Murine MBP or peptide MBP(81-100) was emulsified with 
an equal volume of complete Freund's adjuvant (CFA, Gibco 
Laboratories, Grand Island, NY) supplemented with 4 mg/ml ~ 
tuberculosis H37 RA (Difco Laboratories, Detroit, MI). Mice 
were immunized with a total of 55-75 ~g MBP, or 100 nmoles 
of MBP(81-100) , in equal 50 ~l volumes SC in the hind 
footpads. 
In vitro lymph node cell proliferation assay 
Mice were sacrificed by cervical dislocation ten days 
after immunization. Inguinal and popliteal lymph nodes were 
sharply dissected and excised, and were suspended in Ventrex 
HL-1 serum free medium (Ventrex Laboratories, Portland, ME) 
or complete RPMI (for the MBP(81-100) immunization 
experiment) after crush dissociation. Viable lymph node 
cells were then plated at 3 - 4 x loS/well in 200-250 
~l/well in Falcon 3077 96 well round bottom plates (Becton 
Dickinson & Co., Lincoln Park, NJ), and murine MBP (mMBP) 
(from the same prep as that used in the immunization) or 
HPLC-purified synthetic peptides were added. Four days 
later, 1 ~ci [methyl-3H] thymidine was added to each well 
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and cells were collected 16-24 hours later on Whatman 934-AH 
glass fiber filters (Whatman Co., Maidstone, England) using 
a PHD cell harvester (Cambridge Technology, Inc., Cambridge, 
MA). Counts per minute (CPM) from triplicate or 
quadruplicate wells were determined by liquid scintillation 
counting, and calculated disintegrations per minute (DPM) 
were analyzed where noted. 
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IV. Results 
Elevated response to murine MBP in shiverer mice. 
To determine the effect of endogenous MBP expression on 
the immune response to MBP, non-shiverer and shiverer H-2d 
mice were immunized with MBP, and lymph node proliferative 
responses upon restimulation with MBP were compared. Two 
experiments involving a total of 10 mice were performed. 
Figure 1 illustrates the lymph node proliferative responses 
of H-2d Mbp+ and mbyn; mice observed in experiment 1 (Table 
2a). Mbp+ mice responded poorly to restimulation with mMBP, 
whereas mbyn; mice responded well. In a second experiment, 
Mbp+jmbyn; littermates were also studied, and these mice 
responded similarly to Mbp+ mice (Table 2a). Restimulation 
with purified protein derivative (PPO) of M. tuberculosis 
(25~gjml), a positive control for immunization, gave similar 
responses (ca. 500,000 net dpm in expt. 1, ca. 200,000 net 
dpm in expt. 2) for all animals tested in each experiment. 
Overall, H-2d MBP-deficient shiverer mice were hyper-
responsive to restimulation with MBP compared with MBP-
expressing littermates (P < 0.05). 
Because wildtype BI0.PL (H-2u ) mice respond well to MBP 
immunization and are susceptible to EAE induction, 
similar experiments were performed with H-2u mice. 
Intercross offspring following 1 or 2 backcrosses of 
shiverer mice with BI0.PL mice were screened for MBP and H-2 
genotypes. The response of H-2u mice to mMBP immunization 
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was determined as described above. Four experiments 
involving a total of 26 mice were performed. Figure 2 
illustrates the lymph node proliferative responses of H-2u 
Mbp+, Mbp+ /mbr, and mbr mice observed in experiment 1 (Table 
2b). Mbp+ and Mbp+/mbr mice responded poorly to 
restimulation with mMBP, whereas mbr mice responded well. 
Responses to PPD within each experiment were similar for all 
three MBP genotypes (data not shown). Overall, H-2u myelin-
deficient shiverer mice were hyper-responsive to 
restimulation with MBP compared with MBP-expressing 
littermates (P < 0.05), and Mbp+/mb~ mice responded 
indistinguishably from Mbp+ mice (P = NSD) (Table 2b). 
In both H-2d and H-2u mice, expression of endogenous 
MBP led to a statistically significant reduction in 
responsiveness to mMBP restimulation following mMBP 
immunization. Mbp+ and Mbp+/mbr mice of both haplotypes 
showed similar responsiveness to mMBP restimulation mv~o. 
Elevated responses m shiverer mice map to particular epitopes of MBP. 
To determine the basis for the enhanced responsiveness 
to self MBP immunization in H-2d shiverer mice, lymph node 
cells from mMBP-immunized shiverer and non-shiverer 
littermates were stimUlated in vitro with individual 
overlapping synthetic peptides derived from the 18.5 kD MBP 
sequence (Table 1). Figure 3 illustrates proliferative 
responses to these peptides, and shows that the enhanced 
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responsiveness to mMBP immunization in H-2d shiverer mice is 
largely accounted for by an increased response to a single 
peptide, MBP(81-100) (P < 0.05). In addition, two of four 
shiverer mice studied showed a significant, but lower, 
response toMBP(61-80). As shown in Table 2a, ~p+ and 
~p+/mb~ H-2d mice responded similarly to MBP(81-100) . 
Thus, the hyper-responsiveness of H-2d shiverer mice to mMBP 
immunization is mainly due to hyper-responsiveness, or 
intolerance, to MBP(81-100). 
The ability of MBP(81-100) to prime T cell responses in 
H-2 d mice was then studied. ~p+, ~p+/mb~, and mb~ 
littermates were immunized with MBP(81-100), and in vitro 
proliferative responses to mMBP and MBP(81-100) were 
compared. As shown in figure 4, lymph node cells from 
~p+ and ~p+/mb~ mice responded poorly to invwo stimulation 
with both mMBP and MBP (81-100), while those from mbpW mice 
responded well to both mMBP and (81-100). It appears that 
~p+ and ~p+/mb~ mice are similarly tolerant to self MBP 
and MBP(81-100), and that H-2d shiverer mice are not 
tolerant to an epitope estimated by MBP(81-100). Whereas 
wildtype BALB/c (H-2d ) mice respond poorly to murine (self) 
MBP immunization, wildtype B10.PL (H-2u ) mice respond well. 
A typical epitope map for a B10.PL mouse is shown in figure 
5a, and demonstrates that most of the T cell response to 
mMBP immunization of inbred B10.PL is directed towards the 
N-terminal portion of mMBP, MBP(NAc1-20). Response to this 
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"dominant" epitope is frequently accompanied by lesser 
responses to other, "subdominant", epitopes including 
MBP(31-50) and MBP(121-140) (see chapter 1, "T cell epitopes 
of self myelin basic protein in BIO.PL mice"). To determine 
whether the enhanced response to MBP in H-2u shiverer mice 
is directed towards the dominant epitope, the subdominant 
epitope, or new epitopes, lymph node cells from MBP-
immunized H-2u wildtype and shiverer mice were stimulated in 
vitro with the overlapping synthetic peptide series 
described above. Figure 5b shows that the enhanced 
responsiveness to mMBP in H-2u shiverer mice is largely 
accounted for by an increased response to the wildtype 
subdominant epitope, MBP(121-140) (P < 0.01). No enhanced 
response to the other wildtype subdominant epitope, MBP(31-
50), was observed in H-2u shiverer mice. There was no 
evidence for tolerization of MBP(NAc(1-20»-specific-T cells 
in MBP-expressing mice, and responsiveness to MBP(NACl-20) 
was not demonstrably different between shiverer and non-
shiverer mice (P = NSD). 
In both H-2d and H-2u mice, the observed T cell hyper-
responsiveness to mMBP in shiverer mice is directed towards 
single epitopes, i.e., MBP(81-100) in H-2d shiverer mice and 
MBP(121-140) in H-2u shiverer mice. In wildtype H-2u mice, 
the response to mMBP(121-140) is tolerized and the response 
to mMBP(NAcl-20) is not, suggesting that these epitopes are 
tolerized independently. 
V. Discussion 
MBP as a sequestered self antigen. 
In H-2 d and H-2u mice, the immune response to mMBP is 
reduced when myelin basic protein (MBP) is expressed 
endogenously. MBP is therefore not a sequestered self 
antigen, since its expression leads to tolerance induction 
in normal mice. 
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The brain is one of several organs which are considered 
to be "immunologically privileged" sites (14,40). The 
blood-brain barrier of tight endothelial junctions prevents 
access of both cells and dyes into the brain under normal 
circumstances. Normal cerebrospinal fluid (CSF) , for 
example, has 5 1 lymphocyte per microliter, while normal 
blood has an average of 2200 per microliter (41). In 
addition, the brain lacks conventional lymphatic drainage, 
the usual means for trafficking of antigens to the secondary 
lymphoid organs. An effective anatomic barrier, plus a lack 
of efferent lymphatics, may account for the observed 
prolonged survival of tumor and embryonic allotransplants in 
the brain. These observations have given rise to the 
hypothesis that the brain and its component tissues are 
sequestered from routine lymphoid surveillance. Thus, 
myelin is expected to be a sequestered tissue and MBP is 
expected to be a sequestered antigen. The data presented in 
this report, however, indicate that MBP is tolerogenic, so 
some mechanism must exist for presentation of endogenous MBP 
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to the immune system. Soluble protein exchange between CSF 
and lymph, as has been observed for albumin (42), or 
incomplete integrity of the blood-peripheral nerve barrier 
(43), may provide routes by which endogenous MBP could 
traffic to sites of tolerance induction. 
Both Mbp+ and Mbp+ /mbpN H-2u mice have a non-shi verer 
phenotype. No statistical difference between their 
responses to mMBP immunization was demonstrable. The MBP 
concentration in the brain varies linearly with normal MBP 
gene copy number, but morphometric analysis on Mbp+ and 
Mbp+/mbpN brains has shown no significant difference in the 
thickness of myelin in the myelin sheaths (44). The data 
presented in this report suggest that the amount of MBP 
generated in Mbp+/mbpN mice is sufficient for tolerance 
equivalent to that seen in Mbp+ mice. 
Epitope-specijic tolerance to self MBP in H-? mice. 
Compared to H-2u non-shiverer littermates, H-2u 
shiverer mice are hyper-responsive to MBP(121-140), but 
similarly responsive to MBP(NAcl-20) and MBP(31-50). The 
response to MBP(121-140) in non-shiverer mice is well-
tolerized, whereas the response to MBP(NAcl-20) is not well-
tolerized. The response to MBP(31-50) is poor in both 
shiverer and non-shiverer mice. Thus, T cell tolerance to 
self MBP in non-shiverer H-2u mice appears to be epitope-
specific. 
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Shiverer mice have been found to generate small amounts 
of polyadenylated transcripts of exons 1 and 2 from the 
normal MBP promoter (34). This observation suggests that a 
truncated, 83 amino acid polypeptide that encompasses 
MBP(NAcl-20) and MBP(31-S0) could in theory be translated 
from the exon (1,2) partial MBP transcript. This 
polypeptide has not been observed in shiverer brain using 
anti-human MBP polyclonal antibodies in an RIA with a 
sensitivity of O.S ng/ml (44). However, a truncated 
polypeptide could be present at a low level sufficient to 
induce tolerance. It is possible that a completely MBP null 
mouse might prove to be hyper-responsive to MBP(NAcl-20) and 
MBP(31-S0). In any case, normally myelinated H-2u mice are 
poorly tolerized to MBP(NAcl-20), but well-tolerized to 
MBP(121-140). In addition, the MBP(31-S0) recall response 
is poor in both shiverer and non-shiverer mice, suggesting 
that processed and presented MBP on the APC surface is of 
marginal sUfficiency for MBP(31-S0)-specific T cell 
expansion. 
The murine immune response to the xenoprotein, hen egg 
lysozyme (HEL), also involves epitope-specific tolerance 
(16). Following immunization with HEL in CFA, B10.A mice 
respond to restimulation with at least four different HEL 
peptides, with the greatest proliferative responses found 
due to stimUlation with peptides HEL(20-35) and HEL(46-61). 
Interestingly, induced tolerance to HEL via IV injection of 
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HEL was epitope-specific; tolerant mice did not respond to 
stimulation with HEL(20-35) or HEL(46-61), but did respond 
to minor determinants. These data are similar to our 
observations in MBP-deficient shiverer mice, in that the 
predominant response in shiverers is the best tolerized in 
non-shiverers. 
The basis for these examples of epitope-specific T cell 
tolerance is not known. The TCR/MHC/peptide complex might 
have a threshhold affinity for T cell tolerization and 
activation which is satisfied by some epitopes, but not 
others (16). Alternatively, epitopes might be transported 
with different efficiencies to sites of tolerization (45). 
Finally, central and peripheral APCs might use different 
mechanisms of antigen processing and/or presentation to T 
cells. In this model, certain epitopes would be presented 
by thymic APCs, leading to tolerance, whereas other epitopes 
would be presented in the periphery, leading to activation. 
Although these data suggest that T cell tolerance to 
MBP occurs in mice expressing the protein, we have not 
identified the sites or mechanisms of tolerance to MBP. 
This model does, however, offer the opportunity to correlate 
tolerance to specific self epitopes with their presence at 
sites of tolerization and their chemical affinities for MHC 
and TCR. 
Incomplete tolerance to tolerogenic epitopes in H-? and H-2" mice. 
Tolerance to MBP(81-100) in H-2d mice and to MBP(121-
140) in H-2u mice is frequently incomplete, as 4 of 6 MBP-
expressing H-2d mice responded to MBP(81-100), and 9 of 17 
MBP-expressing H-2u mice responded to MBP(121-140). In 
addition, MBP(121-140)-specific T cells have been isolated 
from normal B10.PL (H-2u ) mice (data not shown). 
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The basis for incomplete tolerance to these MBP 
epitopes is not known. A similar effect was noted in the 
mouse HEL tolerance model (16). One model to explain this 
phenomenon envisions a set of epitope-specific T cell clones 
with different ligand-binding affinities. T cell clones 
with high, but not low, ligand binding affinities would be 
tolerized, resulting in incomplete tolerance to the epitope 
in normal mice. This model would predict that shiverer mice 
would contain epitope-specific T cells expressing unique 
TCRs that are not found in wildtype mice. Alternatively, 
epitope-specific T cells in wildtype and shiverer mice may 
express the same set of TCRs with ligand-binding affinities 
which are borderline for the induction of tolerance. 
Borderline ligand-binding affinities of epitope-specific T 
cells would lead to incomplete tolerance in normal mice. 
We have demonstrated that normal mice are incompletely 
tolerant to particular epitopes of the nervous system-
specific self antigen, myelin basic protein. Incomplete 
tolerance to self proteins has important implications for 
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understanding the etiology of autoimmune disease. 
74 
VI. References 
1. Kronenberg, M., G. siu, L. E. Hood., and N. Shastri. 
1986. The molecular genetics of the T-cell antigen 
receptor and T-cell antigen recognition. Ann. Rev. ImmunoL 
4:529. 
2. Hunkapiller, T., and L. Hood. 1989. Diversity of the 
immunoglobulin gene superfamily. Adv. in Immunol. 44: 1. 
3. Matis, L~ A. 1990. The molecular basis of T cell 
specificity. Ann. Rev. ImmunoL 8: 65. 
4. Sinha, A. A., M. T. Lopez, and H. O. McDevitt. 1990. 
Autoimmune diseases: the failure of self-tolerance. 
Science. 248: 1380 . 
5. Kappler, J. W., N. Roehm, and P. Marrack. 1987. T cell 
tolerance by clonal elimination in the thymus. Cell. 
49:273. 
6. Kisielow P., H. Bluthmann, U. D. Staerz, M. steinmetz, 
and H. von Boehmer. 1988. Tolerance in T-cell-receptor 
transgenic mice involves deletion of nonmature CD4+8+ 
thymocytes. Narure. 333:742. 
7. von Boehmer, H., and K. Schubiger. 1984. Thymocytes 
appear to ignore class I major histocompatibility 
complex antigens expressed on thymus epithelial cells. 
Eur.1. Immunol. 14: 1048. 
8. Lo, D, L. C. Burkly, G. Widera, C. Cowing, R. A. 
Flavell, R. D. Palmiter, and R. L. Brinster. 1988. 
Diabetes and tolerance in transgenic mice expressing 
class II MHC molecules in pancreatic beta cells. CelL 
53:159. 
9. Jenkins, M. K., E. Burrell, and J. D. Ashwell. 1990. 
75 
The effectiveness of T cell stimulation of Ia+ antigen-
presenting cells is determined by costimulatory 
signals, not T cell receptor occupancy. 1. ImmunoL 
144:1585. 
10. Rocha, B., and H. von Boehmer. 1991. Peripheral 
selection of the T cell repertoire. Science. 251:1225. 
11. Schwartz, R.H. 1989. Acquisition of immunologic self-
tolerance. CelL 57:1073. 
12. Klein, J. 1990. Immunology. Blackwell Scientific 
Publications, Cambridge, MA. 
13. Zamvil, S. D., P. A. Nelson, D. J. Mitchell, R. L. 
Knobler, R. B. Fritz, and L. steinman. 1985. 
Encephalitogenic T cell clones specific for myelin 
basic protein. 1. Exp. Med. 162: 2107. 
14. Barker, C. F., and R. E. Billingham. 1977. 
Immunologically privileged sites. Adv.lmmunoL 25:1. 
15. Zamvil, S. S., and L. steinman. 1990. The T lymphocyte 
in experimental allergic encephalomyelitis. Annu. Rev. 
ImmunoL 8: 579. 
16. Gammon, G. and E. E. Sercarz. 1989. How some T cells 
escape tolerance induction. Nature. 342: 183 . 
. 17. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, 
L.-J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, 
and L. M. Nadler. 1991. structure, Expression, 
76 
and T cell costimulatory activity of the murine 
homologue of the human B lymphocyte activation antigen 
B7. 1. Exp. Med. 174: 625. 
18. Hagerty, D. T., B. D. Evavold, and P. M. Allen. 1991. 
The processing and presentation of the self-antigen 
hemoglobin.: Self-reactivity can be limited by antigen 
availability and costimulator expression. 1. Immunol 
147:3282. 
19. Schumacher, T. N. M., M. L. H. Debruijn, L. N. Vernie, 
W. M. Kast, and C. J. M. Melief. 1991. Peptide 
selection by MHC class I molecules. Nawre. 350:703. 
20. Braciale, T. J. and V. L. Braciale. 1991. Antigen 
presentation: structural themes and functional 
variations. Immunol. Today. 12: 124. 
21. Rudensky, A. Y., P. Preston-Hurlburt, S.-C. Hong, A. 
Barlow, and C. A. Janeway Jr. 1991. Sequence analysis 
of peptides bound to MHC class II molecules. Nawre. 
353:622. 
22. Harding C. V., E. R. Unanue, J. W. Slot, A. L. 
Schwartz, and H. J. Geuze. 1990. Functional and 
ultrastructural evidence for intracellular formation of 
major histocompatibility complex class II-peptide 
complexes during antigen processing. Proc. Natl Acad. Sci. 
87:5553. 
23. Winchester, G., G. H. Sunshine, N. Nardi, and N. A. 
Mitchison. 1984. Antigen-presenting cells do not 
discriminate between self and nonself. Immunogenetics. 
19:487. 
24. Lorenz, R. G. and P. M. Allen. 1988. Direct evidence 
for functional self-protein/Ia-molecule complexes in 
vivo. Proc. Natl. Acad. Sci. USA. 85: 5220. 
77 
25. Fritz, R. B. and D. E. McFarlin. 1989. Encephalitogenic 
epitopes of myelin basic protein. m Antigenic 
Determinants and Immune Regulation. Karger, Basel, vol. 
46, pp. 101-125. 
26. Cross, A. H., S. Dolich, and C. S. Raine. 1990. Antigen 
processing of myelin basic protein is required prior to 
recogni tion by T cells inducing EAE. Cellular ImmunoL 
129:22. 
27. Readhead, C., and L. E. Hood. 1990. The dysmyelinating 
mouse mutations shiverer (shi) and myelin deficient 
(mid). Behavior Genetics. 20: 213 • 
28. Dupouey, P., C. Jacques, J. M. Bourre, F. Cesselin, A. 
Privat, and N. Baumann. 1979. Immunochemical studies of 
myelin basic protein in shiverer mouse devoid of the 
major dense line of myelin. Neurosci. Lett 12: 113. 
29. Kirschner, D. A., and A. L. Ganser. 1980. Compact 
myelin exists in the absence of myelin basic protein in 
the shiverer mutant. Naw~. 283:207. 
30. Takahashi, N., A. Roach, D. B. Teplow, S. B. Prusiner, 
78 
and L. E. Hood. 1985. Cloning and characterization of 
the myelin basic protein gene from mouse: One gene can 
encode both 14 kb and 18.5 kb MBPs by the alternate use 
of exons. Cell. 42:139. 
31. DeFerra, F., H. Engh, L. Hudson, J. Kamholz, C. 
Puckett, S. Molineaux, and R. Lazzarini. 1985. 
Alternative splicing accounts for the four forms of 
myelin basic protein. Cell. 43:721. 
32. Roach, A., N. Takahashi, D. Pravtcheva, F. Ruddle, L. 
E. Hood. 1985. Chromosomal mapping of mouse myelin 
basic protein gene and structure and transcription 
of the partially deleted gene in shiverer mutant 
mice. CelL 42: 149. 
33. Molineaux, S. M., H. Engh, F. DeFerra, L. Hudson, and 
R. A. Lazzarini. 1986. Recombination within the myelin 
basic protein gene created the dysmyelinating shiverer 
mouse mutation. Proc. NatL Acad. Sci. USA. 83: 7542 . 
34. Wiktorowicz, M., and A. Roach. 1991. Regulation of 
myelin basic protein gene transcription in normal and 
shi verer mutant mice. Dev. Neurosci. 546: 1-
35. Smith, M. E., 1969. An in vitro system for the study of 
myelin synthesis. 1. Neurochem. 16:83. 
36. Sluka, J. P., S. J. Horvath, A. C. Glasgow, M. I. 
Simon, and P. B. Dervan. 1990. Importance of minor-
groove contacts for recognition of DNA by the binding 
domain of HIN recombinase. Biochemistry. 29:6551. 
37. Landegren, U., R. Kaiser, J. Sanders, and L. Hood. 
1988. A ligase-mediated gene detection technique. 
Science. 241 : 1077 . 
79 
38. Nickerson, D. A., R. Kaiser, S. Lappin, J. Stewart, L. 
Hood and U. Landegren. 1990. Automated DNA diagnostics 
using an ELISA-based oligonucleotide ligation assay. 
Proc. NatL Acad. Sci USA. 87: 8923 • 
39. Gomez, C. M., A. L. Muggleton-Harris, D. G. 
Whittingham, L. E. Hood, and C. Readhead. 1990. Rapid 
preimplantation detection of mutant (shiverer) and 
normal alleles of the mouse myelin basic protein gene 
allowing selective implantation and birth of live 
young. Proc. NatL Acad. Sci. 87: 4481. 
40. Klein, J. 1984. Immunology. Blackwell Scientific 
Publications, cambridge, MA. 687 pp. 
41. Diem, K., and C. Lentner, editors. 1975. m Scientific 
Tables. Geigy Pharmaceuticals, Ardsley, NY. pp. 619, 
635. 
42. Harling-Berg, C., P. M. Knopf, J. Marrian, and H. F. 
Cserr. 1989. Role of cervical lymph nodes in the 
systemic humoral immune response to human serum albumin 
micro infused into rat cerebrospinal fluid. 1. NeuroimmunoL 
25:185. 
43. Peters, A., S. L. Palay, and H. D. Webster. 1991. 
Connective tissue sheaths of peripheral nerves. m The 
Fine Structure of the Nervous System. pp. 384-394. 
80 
44. Shine, D. H., C. Readhead, B. Popko, L. E. Hood, and R. 
L. Sidman. 1992. Morphometric analysis of normal, 
mutant, and transgenic CNS: correlation of 
myelin basic protein expression to myelinogenesis. J. 
Neurochem. 58: 342. 
45. Gammon, G., E. E. Sercarz, and G. Benichou. 1991. The 
dominant self and the cryptic self: shaping the 




Text references to these peptides are given as 
"MBP (peptide) ". "NAcl-20" refers to the N-acetylated 
derivative of the amino-terminal 20-mer. This numbering 
system (31) does not take the exon 2-encoded amino acid 
residues (n=26) into account. Peptide (104-113)/(155-164) 
("E6(-)") is an (exon 5, exon 7)-encoded fusion peptide made 
to mimic the 14 kD MBP isoform (Exon 6(-» protein sequence. 
Table 2: 
Lymph node proliferative responses of a) H-2d and b) H-
2u mice following mMBP immunization. Responses are given as 
net DPMs (DP~ = DP~- DP~~) with associated standard error 
of the difference of the means (SED), and as stimulation 
indices (SIs) (SI = (DPM~/DPMb~). Means are given as an 
estimate of central tendency for each group. SI is assumed 
to be a non-parametric variable, so the wilcoxson rank sum 
test was used to determine statistical significance. "*" 
means that P < 0.05 in the comparison of ~p+ and mbpW mice. 
"i" means that P < 0.01 in the comparison of ~p+ and mb~ 
mice. No statistical difference is demonstrable between 
~p+ and ~p+/mb~ mice. Intra-group variation may be due to 
the use of non-isogenic mice, different batches of mMBP, and 
a calculated variable (SI) for normalization of experiments. 
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Tab1e 1. OVer1appinq Peptides fro. the 18.5 kD Por.. of 
Murine Hye1in Basic Protein 
peptide Name Peptide Sequence Coded by Exon 
NAc1-20 ASQKRPSQRSKYLATASTMD I 
11-34 KYLATASTMDHARHGFLPRHRDTG I 
22-40 ARHGFLPRHRDTGILDSIG I 
31-50 RDTGILDSIGRFFSGDRGAP I 
41-58 RFFSGDRGAPKRGSGKDS I, III 
49-70 APKRGSGKDSHTRTTHYGSLPQ I, III 
61-80 RTTHYGSLPQKSQHGRTQDE III 
68-91 LPQKSQHGRTQDENPVVHFFKNIV III, IV 
81-100 NPVVHFFKNIVTPRTPPPSQ III, IV 
87-114 FKNIVTPRTPPPSQGKGRGLSLSRFSWG III, IV, V 
101-120 GKGRGLSLSRFSWGAEGQKP IV, V, VI 
111-130 FSWGAEGgKPGFGYGGRASD V, VI 
121-140 GFGYGGRASDYKSAHKGFKG VI 
131-150 YKSAHKGFKGAYDAQGTLSK VI 
141-160 AYDAQGTLSKIFKLGGRDSR VI, VII 
151-168 IFKLGGRDSRSGSPMARR VI, VII 
104-113/ RGLSLSRFSWGGRDSRSGSP V, VII 
155-164 
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Table 2a: H-zd ly.ph Node Prol iferation in Vitro After ...u> I~ization 
Expt Animal ntlBP g MBP(81'100) g 
Net DPM SED Net DPM SED 
MBP +/+ 1 . 1 43412 !,7753 3.3 31519 !,691 0 2.7 
2 31519 !,691 0 2.9 30025 !,6099 2.7 
2 3 10595 !,7840 1.9 -1019 +2543 0.9 
4 -6645 !,693 ~ 7906 ~2734 l..1 
Mean 2.1 2.1 
MBP shi/+ 2 1 -517 !,2149 0.9 3284 !,2226 1.5 
2 -39 !,287 1.:.Q 1929 !,280 1& 
Mean 1.0 1.7 
MBP shi/shi 1 183122 !,11775 11.7 153311 !,15694 10.0 
2 235001 !,7402 11.8 189041 !,4617 9.6 
2 3 128075 !,191 08 25.4 155767 +10778 30.6 
4 11125 !,3622 4.3 123313 ~36114 37.8 










































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Effect of endogenous MBP expression in H-2d mice 
on lymph node cell proliferative response to mMBP 
restimulation. Li ttermate H-2d Mbp+ and mbp"" mice were 
immunized with 50-70 ~g murine MBP in CFA. Lymph nodes were 
harvested 10 days later, and 3-4 x 105 viable cells/well 
were incubated with murine MBP for 5 days. One ~Ci 3H- TdR 
was added during the last day, cells were filtered, and CPM 
were counted. Data points reflect the mean of triplicate 
samples, and error bars reflect the standard error of the 
difference of the means. Each dose response curve 
represents the responses of one mouse in experiment 1 (Table 
2a) • 
Figure 2. Effect of endogenous MBP expression in H-2u mice 
on lymph node cell proliferative response to mMBP 
restimulation. Littermate H-2u Mbp+, Mbp+/mbp"" and mbp"" mice 
were immunized with murine MBP in CFA. Lymph nodes were 
harvested 10 days later, and 3-4 x 105 viable cells/well 
were incubated with murine MBP for 5 days. One ~ci 3H- TdR 
was added during the last day, cells were filtered, and CPM 
were counted. Data points relect the mean of triplicate 
samples, and error bars reflect the standard error of the 
86 
difference of the means. Each dose response curve 
represents the responses of one mouse in experiment 1 (Table 
2b) . ~p+/mbpW mouse results were indistinguishable from 
~p+ mouse results (see Table 2b), and were not plotted. 
Figure 3. Effect of endogenous MBP expression in H-2 d mice 
on lymph node 'cell response to MBP peptide stimulation 
following mMBP/CFA immunization. Littermate H-2d ~p+, 
~p+/mbpW and mbpW mice were immunized with 50-70 ~g murine 
MBP in CFA. Lymph nodes were harvested 10 days later, and 
3-4 x 105 viable cells/well were incubated with each of the 
overlapping MBP peptides at 30 ~M for 4-5 days. One ~Ci 3H_ 
TdR was added during the last day, cells were filtered, and 
CPM were counted. Bar heights reflect the mean of 
triplicate samples, and error bars reflect the standard 
error of the difference of the means. Responses of two mice 
of ~p+ and mbpW genotypes (Experiment 2, Table 2a) are 
represented here. Responses of ~p+/mbpW mice were similar 
to those of ~p+ mice, and were not plotted. 
Figure 4. Effect of endogenous MBP expression in H-2d on 
lymph node cell response to mMBP and MBP(81-100) stimulation 
following MBP(81-100)/CFA immunization. Littermate H-2d ~p+, 
~p+/mbpW and mbpW mice were immunized with 100 nmoles 
87 
MBP(81-100) peptide in CFA. Lymph nodes were harvested 10 
days later, and 3-4 x 105 viable cells/well were incubated 
with 1 ~M mMBP or 30 ~M MBP(81-100) for 4-5 days. One ~Ci 
3H- TdR was added during the last day, cells were filtered, 
and CPM were counted. Bar heights reflect the mean of 
triplicate samples, and error bars reflect the standard 
error of the difference of the means. Responses of two mice 
of each genotype are represented here. 
Figure 5. Response of MBP-primed H-2u lymph node cells to 
restimulation with mMBP peptides. A B10.PL (H-2u ) mouse (a) 
or H-2 u Mbp+, Mbp+/mb~ and mb~ mice (b) were immunized with 
55-75 ~g murine MBP in CFA. Lymph node cells were harvested 
10 days later, and 3-4 x 105 viable cells/well were 
incubated with each of the overlapping MBP peptides (30 ~M 
each) for 4-5 days. One ~Ci 3H- TdR was added during the 
last day, cells were filtered, and CPM were counted. Bar 
heights reflect the mean of triplicate samples, and error 
bars reflect the standard error of the difference of the 
means. Responses of three mice of Mbp+ and mb~ genotypes 
(Experiment 2, Table 2b) are represented here. Responses of 
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I. Summary 
The degree of allelic sequence variation within the T 
cell antigen receptor (TCR1) a and ~ loci has not been 
firmly established. It is known that the MHC proteins, the 
natural ligands for the alP TCR proteins, are highly 
polymorphic due to multiple germline alleles, and that this 
MHC allelism is positively selected. The TCR Va and Vp loci 
might therefore also sustain a high rate of sUbstitution and 
subsequent polymorphism as a mechanism for generating 
variation for normal selection processes of tolerance and 
response to pathogens. To test this hypothesis, human Vp8.1 
and 8.2 gene segments and their non-coding flanking regions 
were sequenced and compared to their orthologous sequences 
in chimpanzee, gorilla, pig-tailed macaque, and squirrel 
monkey. In addition, Vp 8.1, 8.2, 8.3, and 8.5 gene 
segments from non-related humans were sequenced and analyzed 
for polymorphism. Inter-species comparisons show that these 
gene segments have sustained duplication, conversion, and 
deletion during 35 million years of anthropoid primate 
evolution. Vp 8.1 and 8.2 coding sequences are generally 
conserved with respect to their flanking non-coding 
sequences, but the regions coding for putative 
complementarity-determining (ligand-binding) regions (CDRs) 
sUbstitute at the same rate as their non-coding flanking 
sequences. Unrelated humans demonstrate minimal V~ 8.1, 
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B.2, B.3, or B.5 coding sequence polymorphism, with only one 
non-synonymous nucleotide sUbstitution (in VfiB.3) noted in 
thirteen individuals studied. We conclude that germline 
sUbstitutions and polymorphism in TCR vfi B.1 and 8.2 
probably do not playa major role in generating TCR fi chain 
protein variation, and infer that the extensive variation 
predicted for T cell antigen receptors must derive primarily 
from junctional and combinatorial diversity. 
1 Abbreviations used in this paper: TCR, T cell antigen 
receptor; MHC, major histocompatability complex; MYA, 




T cells express monoclonal heterodimeric antigen 
receptors (TCRs) on their surfaces (Meuer 1984; Haskins 
1984). The antigen specificity of the T cell is determined 
by the specificity of the T cell receptor (Meuer 1984; 
Dembic 1986), the function of the T cell is defined by T 
cell CD4 or CD8 coexpression (Meuer 1984), and activation of 
the T cell is rate-limited by a B7/CD28 costimulatory signal 
(Gimmi 1991). 
T cells appear to be selected on the basis of their TCR 
specificities. Negative selection, whether deletional · 
(Kappler 1987; Kisielow 1988) or anergic (Schwartz 1990; Lo 
1991) in nature, is contingent on TCR specificity, as is 
positive selection, both for T cell maturation (von Boehmer 
1990) and T cell activation in response to pathogens (Brown 
1991; Hahn 1991). 
The wide range of antigens recognized by the TCR 
requires some means of generating diversity in the ligand-
binding regions of the TCR proteins. To generate this 
diversity, several mechanisms have been proposed, including 
germline V gene segment polymorphism (Plaza 1991; Robinson 
1989; Li 1990), combinatorial V(D)J rearrangement 
(Kronenberg 1986; Kimura 1987), and N region diversity 
(Concannon 1986). Somatic mutation has not been observed 
for rearranged TCR genes, as it has for immunoglobulin genes 
(Tonegawa 1983). 
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MHC proteins, the ligands for the TCRs, are known to be 
highly polymorphic (Klein 1983, 1990). DNA sequence 
polymorphism in these MHC genes is extensive, with non-
synonymous (amino acid-changing) sUbstitution rates 
exceeding synonymous (silent) sUbstitution rates for the 
region coding for the antigen binding cleft of both the MHC 
class I and class II molecules (Hughes 1988, 1989). This 
overdominant (positive) selection (Maruyama 1981) is felt to 
result from a ' potential heterozygous advantage in terms of 
pathogen xenoprotein presentation and subsequent disease 
resistance. This rationale suggests that the T cell 
receptors for these MHC class I and II proteins may also be 
highly diverse in order to prevent failures of recognition, 
or "holes", in the T cell repertoire of an individual 
(Schaeffer 1989; Ogasawara 1987). The degree to which this 
diversity is supplied by variation in individual gene 
segments is not clear. 
To determine the extent of evolutionary divergence and 
extant polymorphism of a model V~ gene segment, human Vp8.1 
and Vp8.2 gene segments were compared to orthologous 
sequences in other primates and to homologous sequences in 
other humans. Non-synonymous nucleotide sUbstitution rates 
were found to be slightly lower than those for non-coding 
flanking sequences, but coding sequence sUbstitution rates 
for the putative complementarity-determining (ligand-
binding) regions (CDRs) 1 and 2 were found to be similar to 
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those of non-coding flanking sequences. Furthermore, study 
of samples of fourteen and ten unrelated humans revealed no 
non-synonymous sUbstitutions within V~8.1 or V~8.2, 
respectively, suggesting minimal polymorphism for these V~ 
gene segments. Although certain TCR V~ gene segment alleles 
may be found to be pathologically relevant, our observations 
together suggest that the predominant basis for TCR protein 
diversity is due not to germline diversity, but rather to 
other mechanisms, such as combinatorial and junctional 
diversity. 
III. Materials/Methods 
Human DNA Samples 
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Human cosmid clones H7.1 and H12.18 were derived from a 
HeLa cell cosmid library. 12.18.1 is an M13 subclone of 
H12.18 containing hV~ 8.1 on a 4.6 kb EcoRI fragment. 
Unrelated human peripheral blood specimens were used (some 
extracted directly, some extracted after B cell line 
transformation) to isolate the germline genomic DNA used for 
PCR templates~ Blood donors were normal or RA patients, and 
did not have MS. 
Non-Human Primate DNA Samples 
Chimpanzee (Pan troglodytes) liver from animal YN86-189 
at Yerkes Primate Center was used to obtain the germline 
genomic DNA used for Southern blots and PCR templates. 
Gorilla (Gorilla gorilla) placenta from animal YB84-131 at 
Yerkes Primate Center was used to obtain the germline 
genomic DNA used for Southern blots and PCR templates. Pig-
tailed macaque (Macaca nemestrina) liver from animal YN88-
210 at Yerkes Primate Center was used to obtain the germline 
genomic DNA used for Southern blots and PCR templates. DNA 
from Rhesus monkey (M. mulatta) YN88-221 was used for some 
Southern blots, as noted. Squirrel monkey (Saimiri 
sciureus) DNA was a gift from Dr. W. H. Li, and was used for 
Southern blots and PCR templates. Cebus monkey (Cebus 
albifrons) DNA was a gift from Dr. R. Higuchi, and was used 
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for Southern blots as noted. 
Southern Blotting and DNA Hybridization 
Ten micrograms of human, chimp, gorilla, macaque, and 
squirrel monkey DNA were digested for each condition for 
each species, and the DNA was size-separated on 0.7-1.0% 
agarose gel. Gels were photographed for migration rates of 
size markers, then transferred to Zetaprobe membranes 
(BioRad Labs,' Richmond, CAl using 0.4 N NaOH. These blots 
were washed three times in 2x SSC (NaCl 0.3 H, Nacit 0.03 H) 
at room temperature, blotted damp, then prehybridized in (5x 
SSC, 1% SDS, 50% formam ide , 25.mM NaH2PO., 1% powdered milk, 
and 0.2 mgjml boiled salmon sperm DNA) for ~ 20 minutes. 
Random primer extension (Feinberg 1983) was used to ~P-label 
double strand DNA probes, and the probes were individually 
hybridized to the blots in the above prehybridization 
solution plus 10% Dextran SO. at 37 C for ~ 16 hours. 
Hybridized blots were washed twice in 2x SSCjO.1%SDS at room 
temperature for 15 minutes, then washed three times in 2x 
SSCjO.1%SDS at 60 C, or more stringently as noted, prior to 
film exposure at -70 C for various intervals. 
DNA Sequencing of Human 1218.1 
Sequenase kit reagents (US Biochemical Co., Cleveland, 
Ohio) were used to perform dideoxynucleotide termination 
sequencing of single (+) strand M13 clone 12.18.1, this 
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clone containing hV#8.1 and its 51 flanking region. six 
percent polyacrylamide gels were poured into 38 x 50 cm 
sequigen gel plates (Bio-Rad, Richmond, CAl. 
Oligonucleotide primers were successively synthesized (AB! 
380B, Cal tech Biopolymer Synthesis and Analysis Resource 
Center) as new sequence data was generated. 
The (+) strand of H12.18.1 was sequenced over a 2.0 kb 
region from the 3 1 end of the second exon of human V# 8.1 to 
1.5 kb 51 of the first exon. From this sequence, primers 
were designed and synthesized to sequence the complementary 
strand, and it was sequenced in a similar fashion. 
Cloning of Primate Vp 8.1 & 8.2 Gene Segments 
PCR amplification primers AP7 (5 1-AGG TAT TGG CAG GGC 
TAC ATT CCT TCC-3 1) and AP2 (5 1-AGC TTA AGG AGA AGG GGA AAC 
ACC GGG TTT-3 I) were then designed based on known 12 °.18.1 
sequence, and these were used to obtain 2.0 kb PCR products 
from human cosmid H7.1 as well as from chimp and gorilla. 
PCR amplification primer pairs [AP8 (5'-AGG GAC TGG CTG AGC 
TTT GC-3 1) and AP2 (above)] or [AP9 (5 1-AAA GCC AAC AGG GAC 
TCT GC-3 1) and AP2] were used to obtain ca. 2.0 kb PCR 
products containing macaque V# 8.1 and 8.2 orthologues. PCR 
amplification primer pairs [APSM5 (5 1-CAA AGC CAA CAA GGA 
CTG GC-3 1) and APSM3 (5 1-GAT CCA TCA GGC CTC TCA GC-3 1)] or 
[8130 (5 1-GAG GTG ACA GAG ATG GGA CA-3 1) and SP2 (5 1-TTT CTG 
CAC AGG AAA GGG GT-3 1)] were used to obtain 1.8 kb and 0.3 
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kb PCR products containing the squirrel monkey v~ S.5 
orthologue. PCR amplification primers APl (5 ' -GAT CCA AGT 
TGG GGG TGG TGG CCC ATT CAG-3 ' ) and SP2 (above) were used to 
obtain 0.6 kb PCR product containing the squirrel monkey Vp 
S.l orthologue. PCR products were filled in with T4 DNA 
polymerase, kinased with PNK, then blunt-end cloned into 
Sma-cut de-phosphorylated M13mp(10 or lS) RF. Ligation 
mixes were used to tranfect F' (+) competent cells (Amersham 
Co., Arlington Heights, IL), clear plaques were picked and 
expanded, and clonal single strand DNA in the supernatants 
was purified. 
DNA Sequencing of Primate Vf3 8.1, 8.2 
The 2.0 kb human AP7-AP2 PCR product was cloned into 
M13mpl0, and individual subclones "S.4" (+) and "S.5" (-) 
were sequenced using dideoxy nucleotide termination methods 
as described above. This double strand sequence was used as 
the benchmark for comparison of human Vp S.2 and primate 
orthologues of these two gene segments. The 2.0 kb human 
AP7-AP2 PCR product containing human Vp S.2 was cloned into 
M13mpl0, and individual subclones IS.6" (+) and IS.l.l" (-) 
were sequenced. 
The 2.0 kb chimpanzee AP7-AP2 PCR product was cloned 
into M13mpl0. Multiple individual subclones were sequenced, 
and only one set of sequences was observed. Representative 
clones "2.16" (+) and "2.1" (-) were found to be 
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complementary. 
The 2.0 kb gorilla AP7-AP2 PCR product was cloned into 
M13mp10. Multiple individual subclones were sequenced, and 
two sets of sequences were observed. Representative clones 
"3.11" (+) and "3.2" (-) were complementary, and clones 
"3.12"(+) and "3.1"(-) were complementary. 
The 2.0 kb macaque AP7-AP2 PCR product was cloned into 
M13mp10. Multiple individual subclones were sequenced, and 
multiple sites of non-complementarity were noted. Two new 
upstream primers differing by a deletion in one of the 
macaque gene segments, APB and AP9, were designed. The 1.9 
kb macaque APB-AP2 and AP9-AP2 PCR products were cloned into 
M13mp10, and multiple individual subclones were sequenced. 
APB-AP2 clones "1.1.4"(+) and "1.1.B" (-) were 
complementary, and AP9-AP2 clones "2.4"(+) and "2.B" (-) 
were complementary. 
The 2.0 kb squirrel monkey AP7-AP2 PCR product was 
sequenced, and only end sequence was obtained. The 1.7 kb 
AP6' (5'-CCT TGC CAC ATA ATT TAA CAC -3')-SP2 PCR product 
was sequenced and non-Genbank, indeterminate sequence was 
obtained. The 1.B kb SM5-SM3 peR product was sequenced, and 
was found to be most similar to human VpB.5. Selected 
clones were sequenced using synthetic fluorescent primers 
(Smith, 19B7) and analyzed on the ABI 370A DNA sequenator 
(ABI, Foster city, CA). The 0.6 kb AP1-SP2 PCR product was 
sequenced, and was found to be most similar to hVP B.1. No 
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further S' flanking sequence from the squirrel monkey hV~8.1 
orthologue was amplifiable with multiple available primers. 
peR of (Unrelated) Human VjJ 8.1,8.2,8.3, and 8.5 
PCR primer pairs were designed from published sequences 
(Siu, 1986) to specifically amplify Vp 8.1, 8.2, 8.3, and 
8.S gene segments. Vp 8.1 was amplified with primer VB8.1-1 
(S'-ATG CAG CCT CCT CTT AAA GAA-3') and primer VB8.1-2 (S'-
GAA GGG GAA ACA CCG GGT-3'). Vp 8.2 was amplified with 
primers VBS.2-1 (S'-ATG CAG CCT CCT CTT AAA GTT-3') and 
VBS.2-2 (S'-GAA GGA GAA ACA CCA GGG-3'). Vp S.3 was 
amplified with primers VBS.3-1 (S'-GCT CCT CTG CTG TGT GGT 
T-3') and VB8.3-2 (S'-GAC CAA ACC ACT AGC ACA A-3'). V~ S.S 
was amplified with primers VBS.S-1 (S'-CTG CCT GAT TCA TCT 
CCC AA-3') and VBS.S-2 (S'-GCC GAG TCC CCC TGC TCT GCA-3'). 
PCR was performed using a Perkin-Elmer Cetus 
(Emeryville, CA) "DNA Thermal Cycler" in a reaction mix 
containing DNA polymerase (Cetus, 10U/ml final 
concentration), the reaction buffer recommended by the 
manufacturer, dNTPs (final concentration 20. uM), primers 
(final concentration 0.3 uM each), and DNA template (100. ng 
genomic DNA). The cycle profile was an initial denaturation 
for 3 minutes at 94 C, then 3S cycles of 1 minute at 94 C, 2 
minutes at 60 C, and 3 minutes at 72 C, with a final 
extension for 7 minutes at 72 C. 
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DNA Sequencing of (Unrelated) Human Vf3 B.1, B.2, B.3, and B.5 
For purposes of DNA sequencing, a large scale peR was 
performed in 200 uL according to the conditions described 
above. Mineral oil was not used during the amplification, 
so that ethanol precipitation could be done in the same tube 
as the amplification. The concentrated peR products were 
purified by electrophoresis through 1% low-melting point 
agarose, and the amplified products excised from the gel. 
Sequencing of the peR products was performed in 96 well 
assay plates essentially according to Kretz (Kretz 1989) 
The sequencing primers used were the same as the DNA primers 
used for the original amplification. 
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IV. Results 
Fine restriction map of vp 8.1 & 8.2 
Southern blots were hybridized with Vfi8.1 coding 
sequence (cDNA YT35) (Siu 1984) or 5'flanking sequence (AP7-
8159) probes. The resulting autoradiograms allowed 
assignment of orthologous sequences to particular fragment 
sizes, and these were used to restriction site map the Vfi 
8.1 and 8.2 region. Two of these autoradiographs are shown 
in Figures 1A and 1B in order to demonstrate the absence of 
Vfi8.2 in the two chimps studied here, and the absence of the 
second gene segment in the cebus monkey. Figure 2 shows an 
autoradiograph of a squirrel monkey Southern blot probed 
with YT35, and suggests that only one fragment in each lane 
hybridizes with the probe. Both gene segments are present 
in human, gorilla, and macaque. Figure Ie shows the derived 
restriction map for this region in human, chimp, gorilla, 
macaque, and squirrel monkey. 
Sequence alignment of primate Vp 8.1 & 8.2 
Human Vfi 8.1 and 8.2 DNA coding sequences are 98% 
similar, appear to be the result of a recent DNA sequence 
duplication and, as such, are defined as paralogous 
sequences. Sequence overlap comparison of the complete 
human sequence (data not shown) demonstrates 3.3 kb 
duplicands, each containing one paralogue, which are 
juxtaposed and in the same orientation. The junction of 
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these duplicands is identical in human, gorilla, and 
macaque, arguing that the duplication event predated the 
divergence of these species (ca 25 MYA). Figure 3 shows the 
alignment of 2 kb DNA sequence fragments containing human v~ 
8.1, human v~ 8.2, and their primate orthologues. 
Phylogenetic diversity 
Parsimony analysis of the nucleotide sUbstitutions was 
performed, and trees requiring the least number of changes 
between sequences from human, chimp, gorilla, pig-tailed 
macaque, and squirrel monkey were made. The phylogenetic 
arrangement of these sequences, illustrated in Figure 4, 
suggests that the V~8.1/2 ancestral gene segment was 
duplicated sometime after the old world monkey (OWM)-new 
world monkey (NWM) divergence (ca. 35 MYA). This is 
supported not only by the V~ DNA sequence phylogeny, but 
also by the fact that we find no evidence of a duplication 
product in the cebus or squirrel monkeys (see Figures lA, 
IB). The phylogenetic arrangement of primate Vp 8.1 and Vp 
8.2 DNA sequences and the physical map indicate that the 
last common ancestor of chimpanzee and human had both Vp 8.1 
and Vp 8.2 orthologous gene segments, and that at least some 
chimpanzees have deleted the Vp 8.2 orthologue. 
The phylogenetic tree obtained from the entire sequence 
suggests that the Vp8.1 and V~8.2 gene segments arose 
independently in the hominoid common ancestor (human, 
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chimpanzee, and gorilla) and in a macaque ancestor. Those 
findings were quite strongly supported. Additional changes 
to the most parsimonious branching arrangement were required 
to group together all of the Vp B.1 orthologous sequences 
and all of the Vp B.2 orthologous sequences (VP B.1 and Vp 
B.2 defined by physical map position). Upon further 
inspection of the sequence data, it became apparent that the 
5' 700 bp suggested a branching arrangement that supported 
separate VpB.1 and VpB.2 gene lineages, while the rest of 
the sequence data continued to strongly support the overall 
phylogenetic tree (Figure 5). The incongruency between 
these two phylogenetic branching arrangements suggests that 
some additional genetic mechanism was acting on these gene 
sequences. A pattern similar to this has been observed in 
the T-globin genes of primates. In this latter case, in the 
time since a tandem 5 kb duplication in an anthropoid 
ancestor, more than 15 separate gene conversion events have 
homogenized T1 and T2 genes in human, chimpanzee, gorilla, 
orangutan, and rhesus monkey (Slightom 19B7). If two such 
gene conversion events were hypothesized, one in a hominid 
ancestor and one in a macaque ancestor, then the 
phylogenetic branching arrangement of the 3' VPB region can 
be reconciled with that of the 5' VPB region and the 
physical map. 
with regard to the species branching arrangement 
suggested by these V~B.1 and V~B.2 sequences, human and 
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chimpanzee are most closely related, followed by gorilla, 
macaque, and squirrel monkey. The most controversial aspect 
of this arrangement is the human, chimpanzee and gorilla 
placement. In the phylogenetic tree shown in Figure 5, the 
human-chimp grouping is supported by thirteen nucleotide 
positions. The next most parsimonious arrangement places 
human with gorilla, though seven additional changes are 
required to accommodate this arrangement. The grouping of 
human with chimpanzee is consistent with a growing body of 
molecular evidence from rRNAs, mitochondrial sequences, 
immunoglobulins, and globins (Koop, 1989). 
Divergence analysis 
The differences in DNA sequences listed in figure 3 
were analyzed for non-coding sequence (positions 1 to 700, 
positions 70l-end), and coding sequence (non-synonymous 
substitutions, synonymous substitutions). These data are 
summarized in Table 1. Non-coding sequence divergence 
values obtained from these orthologous Vp gene region 
comparisons among human, chimpanzee, gorilla, macaque, and 
squirrel monkey are similar to values obtained from other 
non-coding sequences, most notably those from a 10 kb 
stretch of DNA including the p-globin locus (Koop, 1989) 
(Table 2). Overall, non-synonymous coding differences are 
less than these non-coding differences (p < 0.01, wilcoxson 
Signed Rank test), demonstrating relative conservation. 
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The boundaries of the complementarity-determining 
(ligand-binding) regions (CDRs) of the T cell receptor V 
gene segments have been estimated (Clothia, 1988) and 
identified in our Vfi coding sequence data. We used the 
polypeptide KPISGHNSLF (positions 24-33) as being consistent 
with CDR I, and used the polypeptide IYFNNNVPIDDSGMPE 
(positions 47-63) as being consistent with CDR 2. The 
nucleotides coding for these residues were then compared 
across species. The divergence values for these comparisons 
are given in Table 2, and indicate that non-synonymous 
differences within CDRs 1 & 2 were indistinguishable from 
non-coding differences (p = NSD, wilcoxson signed Rank 
test). This suggests that sUbstitutions in functionally 
critical regions of the Vfi 8.1 and 8.2 gene segment products 
occur freely, but are neither positively (Maruyama, 1981) 
nor negatively selected. 
Human V'p 8.1 polymorphisms 
Two alleles of human Vfi 8.1 from a single individual 
(from cosmids 7.1 and 12.18) were compared across the entire 
2 kb fragment. Three polymorphisms were found, all in non-
coding sequence, and are illustrated in the sequence 
comparison in Figure 3. The first polymorphism (CIT) is 
located 1.28 kb 5' to Vfi8.1 exon 1 at position 235. The 
second polymorphism (CIT) is located 0.98 kb 5' to Vfi8.1 
exon 1 at position 542. The last polymorphism (A/G) is 
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located 1.05 kb 5' to Vp8.1 exon 1 at position 466. This 
A/G polymorphism involves a Bam HI restriction site, has 
previously shown to be present at a bi-allelic frequency of 
50% (Concannon 1987), and is relevant in human disease 
correlations (see discussion). As shown in the fine 
restriction map in Figure 2, this Bam HI site is present in 
all the other species studied, arguing that the second human 
allele lost the site through an A -> G sUbstitution. 
Vp 8.1 coding sequences from fourteen (14) unrelated 
humans (28 chromosomes) were compared, and no polymorphisms 
were observed. 
Human Vf3 8.2 polymorphisms 
Vp 8.2 coding sequences from ten unrelated humans (20 
chromosomes) were compared, and two polymorphisms were 
observed. The first is located in the intron at position 
1773, and involves a C <-> T sUbstitution. The allelic 
frequency was 90% C and 10% T. The second is located in the 
second exon at position 1875 and involves a C <-> T 
sUbstitution. This change is synonymous with respect to 
translated sequence. The allelic frequency is 90% C and 10% 
T. Both of these sUbstitutions were noted to be homozygous 
in the same individual, and absent in the other individuals 
studied. 
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Human polymorphisms in VjJ 8.3 
Vp 8.3 coding sequences from thirteen unrelated humans 
(26 chromosomes) were compared. One polymorphism was 
observed at position 1816, involves a C <-> G substitution, 
and results in a His -> Asp amino acid sUbstitution at 
position 10. The allelic frequency is 62% C and 38% G, and 
the alleles are in Hardy-Weinberg equilibrium (E(x)= 5 C/C, 
6 G/C, 2 GIG; O(x) = 5 C/C, 6 G/C, 2 GIG). 
Human polymorphisms in VjJ 8.5 
Vp 8.5 is a pseudogene in humans (siu 1986). Vp 8.5 
coding region sequences from seven unrelated individuals (14 




The data in this report suggests that the region 
containing Vp 8.1 and 8.2 is mechanically active. The 
proposed dynamics of duplication, gene conversion, and 
deletion which have apparently occurred during the last 35 
MY of primate evolution are illustrated in figure 4. 
We have shown that vp 8.1 is paralogous to Vp 8.2 due 
to duplication of a 3.3 kb region containing the 
prototypical gene segment. The duplicands are juxtaposed 
and in the same orientation. Duplicand junctions are 
identical in species which contain both duplicands, 
demonstrating that a single duplication event predated their 
speciation (ca. 25 MYA). The time of occurrence of the 
single duplication event is suggested by Southern blot 
analysis and can be estimated from the phylogenetic tree. 
Single observed gene segments in cebus and squirrel monkeys 
suggest that they represent pre-duplication organization; if 
so, the Vp 8.1/8.2 duplication event occurred since the Old 
World-New World monkey divergence (ca. 35 MYA). This allows 
estimation of the timing of the duplication to between 25-35 
MYA. Vp 8.1 vs. Vp 8.2 non-coding sequence divergence 
values of 7.5 -10.% (first 700 bases, inside duplication, 
outside putative conversion) suggest that the duplication 
event occurred 22-29 MYA (assuming neutral rate = 1. 7 X 10.9 
(Koop 1989). The Vp 8.2-containing duplicand has been 
deleted in the two chimpanzees studied here at some time 
since the Homo-Pan divergence (ca. 5 MYA). 
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The phylogenetic tree shows that both macaque gene 
segments segregate distinctly from the Vfi 8.1 and 8.2 
branches of the hominoid lineage, suggesting that gene 
conversion events have occurred in both lineages during 
primate evolution. The directions of the gene conversion 
events is difficult to determine, however. Since divergence 
between Vfi 8.1 and 8.2 orthologues is generally greater than 
human-macaque divergence, the conversion events in the 
hominoid and macaque lineages may have employed alternate 
duplicands as the donor. The timing of these putative 
conversion events can be estimated from the SUbstitution 
data. As illustrated in figure 5, the presumed converted 
region involves the 3' 1.3 kb of each duplicand, of which 
the non-coding portion of this is the 5' 800 base pairs. 
For this intra-duplicand, intra-conversion region, human Vfi 
8.1 cf. 8.2 differ by 7.8%, gorilla Vfi 8.1 cf. 8.2 differ by 
9.6%, and macaque Vfi 8.1 cf. 8.2 differ by 5.5%. These data 
suggest that the gene conversion event in the hominoid 
lineage occurred between 23-28 MYA, and that the gene 
conversion event in the macaque lineage occurred 
approximately 16 MYA. 
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VariLZtion 
We have shown that a relevant V~ gene segment is 
evolutionarily conserved overall, but freely substituted in 
regions which probably code for ligand-binding portions of 
the TCR protein. We were unable to demonstrate positive 
selection for sequences which code for CORs 1 & 2. 
Consistent with this is the observation that no non-
synonymous sUbstitutions were found in comparison of V~ 8.1 
and 8.2 from multiple unrelated human individuals. The only 
non-synonymous sUbstitution we found was for position 10 in 
the V~ 8.3 protein, a position outside the predicted CORs, 
this second allele noted in 10 of 26 chromosomes studied. 
Compared to non-coding flanking sequences, overall 
V~8.1 and 8.2 non-synonymous sUbstitution rates were 
slightly conserved. We observed an overall non-synonymous 
sUbstitution rate of 1-1.5 x 10~ changes/site/year, 
comparable to that of immunoglobulin (Ig VH = 1.07 ± 0.19 x 
10~, Ig gamma1 = 1.46 ± 0.13 x 10~). Non-Ig superfamily 
members tolerate more (e.g., gamma interferon = 2.79 + 0.31 
x 10~) or less (a globin = 0.55 + 0.11 x 10~, insulin = 0.13 
± 0.13 x 10~) non-synonymous substitution, these differences 
presumably related to functional constraints on the protein 
(Li 1991). 
Compared to non-coding flanking sequences, CDR 1 and 2 
non-synonymous sUbstitution rates were not conserved. We 
observed a CDR 1 and 2 non-synonymous sUbstitution rate of 
118 
1.5-3.0 x 10~ changes/site/year for V~ 8.1 and 8.2, but 
failed to demonstrate statistically significant positive 
selection for these regions. By doing so, we have shown 
that T cell antigen receptor does not use positively 
selected germline V~ polymorphism to generate the high 
degree of TCR variability expected prior to positive and 
negative selection events. Random combinatorial 
rearrangement of multiple gene segments with junctional 
variability, along with random combinatorial pairing of 
translated products of productive a and ~ gene 
rearrangements, are apparently sufficient for the generation 
of a selectable set of T cell antigen receptor proteins 
(TCRs) on T cells. 
The absence of positive selection for TCR CDR 1 and 2 
differs from what has been observed for the TCR analogue, 
immunoglobulin, and for the TCR ligands, the MHC class I and 
II proteins. The hypervariable regions of rearranged Ig 
genes are correlated with the crystallographically defined 
ligand-binding regions (complementarity-determining regions, 
CDRs). In some immunoglobulin genes, CDR non-synonymous 
(amino acid-substituting) nucleotide SUbstitution rates 
exceed synonymous (amino acid-conserving) SUbstitution 
rates, demonstrating positive selection for high amino acid 
variation in these ligand-binding loops of the 
immunoglobulin (Tanaka 1989). The picture that results for 
Ig, and now TCR, is that of selection-chimeric proteins 
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which are conserved except at ligand-binding sites, where a 
spectrum of neutral to positive selection occurs. This 
occurs in spite of the fact that tens of V gene segments are 
available for Ig L/H and TCR Q/P loci for rearrangement, and 
that Ig can hypermutate rearranged Ig genes to maximize 
ligand-binding affinity. 
Unlike immunoglobulin, which recognizes a three-
dimensional ligand in liquid or solid phase, the T cell 
receptor is constrained to recognize short peptides, 
catabolized at sites of intracellular processing, which are 
non-covalently bound to, and presented by, self major 
histocompatability complex (MaC) proteins. MaC class I 
protein structure has been determined crystallographically, 
and the ligand-binding site has been defined in terms of 57 
amino acid residues in the Q 1 and Q 2 domains (Bjorkman 1987). 
Nucleotide SUbstitution rates in the sequences coding for 
these ligand-binding residues have been compared between 
mouse and human, and it is found that non-synonymous rates 
exceed synonymous rates (Hughes 1990), arguing that amino 
acid variability is positively selected for (Maruyama 1981). 
This empirical observation is consistent with an advantage 
which would accrue to individuals able to bind more, rather 
than fewer, of the foreign peptides generated by antigen 
processing. Because of this focal positive selection, 
multiple alleles would be expected for a given locus, and a 
snapshot of human and mouse confirms this high degree of MaC 
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protein polymorphism for both class I and class II loci 
(Klein 1986). Amino acid variation in the TCR Vp (8.1,8.2) 
CDRs 1 and 2 is neither positively nor negatively selected 
for, and these Vp gene segments are consequently minimally 
polymorphic. The minimal variation in vp sequence which we 
observed does not rule out the existence of such pathogenic 
Vp gene segment alleles. 
Relevance 
Disease risk for a variety of human autoimmune diseases 
can be stratified by MHC allele, arguing that pathogenic 
TCR-peptide-MHC combinations exist in these individuals. 
Similarly, TCR alleles may also confer autoimmune disease 
risk, and disease association studies suggest this 
possibility. 
Although particular Vp alleles have not been proven to 
be etiologic for an autoimmune disease at this time, disease 
associations with RFLPs within the T cell receptor a and p 
loci suggest that pathogenic Vp alleles could increase 
autoimmune disease risk, much as has been observed for MHC 
alleles (Klein 1990). Systemic lupus erythematosus, for 
example, has been associated with a TCR Ca/PstI polymorphism 
(Tebib 1990), and insulin-dependent diabetes mellitus 
(McMillan 1990), Graves' disease (Demaine 1987), Hashimoto's 
thyroiditis (Ito 1989), and membranous nephropathy (Demaine 
1988) have been associated with a TCR CP/BgIII polymorphism 
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(Robinson 1985). 
In particular, gene segments in linkage dysequilibrium 
with the BamHI/V~8.1 RFLP described in this paper (including 
V~ 12 (11 kb 5'), V~ 8.1 (1.0 kb 3'), V~ 8.2 (4.3 kb 3'), 
and V~ 8.3 (also 3') may be relevant to the pathogenesis of 
a number of human autoimmune diseases. Multiple sclerosis, 
a T cell-mediated autoimmune disease of the central nervous 
system, has been associated with the V~8/BamHI (described 
herein) - V~ll/BamHI RFLP haplotype (Beall 1989) and the 
V~12/BamHI (the same BamHI polymorphism as detected with 
V~8) - V~12/HindIII - C~/BgIII RFLP haplotype (Seboun 1989). 
The V~8-V~11 haplotype association may reflect an MS 
susceptibility gene amongst TCR V~, rather than TCR D~, J~, 
or C~, gene segments (Charmley 1991). Recently, V~12 was 
found in productive TCR rearrangements of T cells from three 
patients with MS (Lee 1991), and was found to be used in T 
cells specific for one of the T cell epitopes of human MBP 
(Wucherpfennig 1990). This same V~8/BamHI polymorphism has 
also been associated with rheumatoid arthritis in HLA DR4+ 
individuals (Funkhouser 1992) and HLA-random individuals 
(Gao 1988). 
Since DNA coding sequence polymorphisms have been 
identified in V~l (Robinson 1989), V~ 6.7 (Posnett 1990; Li 
1990), and (V~2.1, 5.3, 7.2, 8.2, 12.4, and 16) (Plaza 
1991), of which several are non-synonymous (V~l, V~ 2.1, V~ 
5.3, 6.7, and V~ 13.4), it is reasonable to suspect that 
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the "disease susceptibility genes" linked to VI3 RFLPs in 
disease association studies are in fact TCR VI3 gene segment 
alleles. However, particular disease-associated VI3 alleles 
have not yet been identified for a T cell autoimmune 
disease, even though reproducible linkage studies imply 
their existence. 
This project sought to determine to what degree human T 
cell antigen receptor protein variation is attributable to 
DNA sequence variation in V gene segments. V138 gene 
sequences within humans were compared to gain a sense for 
the role of polymorphism in creating diversity among higher 
primates, and hV138.1 and 8.2 orthologues in other primates 
were compared to gain a sense for the role of natural 
selection in conservation or the promotion of change. No 
evidence for positive selection of variation in DNA regions 
coding for ligand-binding domains was observed, and minimal 
polymorphism amongst unrelated humans was observed. 
Individual germline VI3 gene segment variation appears to be 
a minor contributor to the spectrum of T cell antigen 
receptor protein diversity. 
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Non-coding vs. coding sequence divergence. Divergence 
values are given for non-coding flanking sequence and coding 
sequence for the V# 8 subfamily gene segments studied. Non-
coding sequence is subdivided into regions which have 
probably undergone gene conversion events ("700-end") and 
those which have probably not ("1-700"). coding sequence 
analysis is subdivided into changes which result in an amino 
acid sUbstitution ("non-synonymous") and those which do not 
("synonymous") (Saitou and Nei 1986). Divergence is 
expressed as DNA sequence percentage difference. 
Table 2: 
Non-coding vs. non-synonymous coding sequence 
divergence. Non-synonymous coding sequence divergence is 
estimated for the entire coding sequence and for the 
putative CDRs. These data are compared to non-coding 
divergence estimates for non-coding flanking sequence and 
for the globin P locus. Rates are calculated in units of 
10~ changes/site/year. The wilcoxson Sign Rank test was 
used to determine statistically significant differences 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Primate genomic southern blot autoradiographs and 
restriction map for human Vp 8.1 and 8.2, and their 
orthologues. Southern blots were probed with 32p-labelled 
YT35 cDNA and washed in 0.5X SSC at 60 C. Human Vp 8.1 
migrates as a 2.1 kb BamHI fragment and as a 4.8 kb EcoRI 
fragment. Human Vp 8.2 migrates as a 3.3 kb BamHI fragment, 
and as a 2.1 kb EcoRI fragment. Figure 1C shows the 
proposed restriction map, derived from both Southern blot 
and sequencing data. The bars over "8.1" and "8.2" estimate 
the YT35 cDNA probe. Bold lines indicate the availability 
of sequence data. Brackets indicate the borders of the 3.3 
kb duplicands, and parentheses indicate the absence of a 
duplicand. 
Figure 2. Genomic Southern blot autoradiograph of squirrel 
monkey DNA. This Southern blot was probed with 32p-labelled 
YT35 cDNA (human Vp 8.1) and washed under the listed 
conditions. Black dots indicate the bands which remained 
after washing at O.lX SSC, as shown in the phosphor imager 
data in the lower panel. 
Figure 3. Sequence comparison of human Vp 8.1, human Vp 
8.2, and their orthologues in chimp, gorilla, macaque, and 
squirrel monkey. Absence of symbols indicates identity of 
136 
bases and asterisk (*) indicates deletion of bases. H = 
human, C = chimp, G = gorilla, R = macaque, and S = squirrel 
monkey. 
Figure 4. Proposed dynamics in the evolution of the Vfi 8.1 
and 8.2 region. Open rectangles indicate the Vfi 8.1 and 8.2 
gene segments. 
Figure 5. Phylogenetic trees for different portions of the 
compared 2.1 kb sequence. Different phylogenetic trees 
resulted from parsimony analysis (Fitch, 1971) of the 
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H8 . J 
R! . 4 
He .5 • 
C C T MT T 
• •.• 7 7 ---------+---------+ __ _______ + _________ +--______ +---___ -+-________ +-__ ______ +-_______ + _______ +-___ +_-------+ 1440 
H,I • 1 c:x:crGATlCA~1'OCAG:X:"1"CAAA····· •••• " *CARlOt rotXXICIU; ltLCCCAT'l'CAG1'CA~TGCA__rtC1C*'t'G(XX;ATAAAA'1'C'I'CACA 
Itl.lb C A GAG C C T •••••••••• ""CAIC 1G C GT "l"OIXXX: TTCA AT C ATGCA""TTC C""'"'J'CC CA A AA1C ICA 
H8 .2 C A eN; C G T ............... fIG .... '!C C CT 1'G'QXC TTCA AT C AT'GCA*T1C C-TGC CA A AA1'C leA 
C' . 1 C A GAG C G T •••••••••• -c ••• '1C C GT TCnX:C TTC'A AT G A'TOCArrtC C·TGG CA A AA1C ICA 
CI . 2 C A GAG C G T ••• ....... acNIG CG C GT 1'QXCC T1'CA AT C A1a:A*TIC c..-,a; CA A AATC ItCA 
C8.1 C A GAG CAT ••••• * •••• *CAIIC 1G G Gt 'ICIX'CC T'fCA AT C A1'GCA*TIC c.'!CC GA A UTe ICA 
R8 . 2 C A GAG C G 7 •••• fI* •• fI·.TAIIC 'IG C C'r TGGCCX: TtCA AT G ATGCA*'tCT Cen;& GA A JCIC IC.A 
R.8.1 A T ax: C C T ... fI ....... MIIC '1G C G1' 'ICIX'CC ATCA Ie. C ATCTA*t'CC C·TGG GA A AA.'IG ICA 
SI.5 C A MA TAG ••• *Q;ATTT'1'CX:IIIC 1G C GT "l"OIXXX: TlCA. AT C ATfXA-a:T C.NJG II:; A ICYA TTY 
SI.l • •• ••••• ••• . .. .. •• • • • ••••••••• • • . ...... .. ... . .. .. .... . 
B8. J . . . ........... 'ta: n "CA CA""'CIIG GA'IG AT C TaXXX:TTI' IC'rCt a;; G CAQG TAG 
R8 . 4. C A GAG eGA TAAGCIGCTT'TCMA 1.'C A GT 'I'CGCXX: TICA. IC. C A1'GCA""1'C1' C-rcT CA A AA'IG N.:A 
al.5 C A AltA T G C **~ '1C C G1' 1'Q;tXC T'fCA Tr A ATGCA""'ICT C-TQ; CG A AA.1C a:A 
----+------+--------+--------+-, ----+----<-- --+-------+----_ .• ,----+- _--+ 15'0 
BI . l AAATl'CA:tiJCIIIGCICATCr'l'CICI.GAilQ'X:CCJGGICIJGAATA~~1'CX'1'GCt~ 
H • • lbAAATlCATTJ'CTT GCTCAT C'lCIC CA-OCO: OC'lCTJIGAA'TAT1C A ., 1GC'1C'T T T IC1CCT NXT TOe 1'CCC a::A C C T CCA 
H • • 2 AAATt'CA'tT'rCTT G'CTCAT T'1CAC CA'*CCIX a.TC'1'GCAATATTC A ar 'IGC'ICT T T GC1CCT NX'£ 'nX' 1'DX GCA C C 'f CAA 
C'.1 AGATTCATTI'CTt OC'ICA'T C'tCIIC CA*Cn:X: CC"l'C'TCCAA'ICTtC .. ar 'IIX"'!C't T T ICtO:T JD::T 1'GC to::c a:A C C 'f CCA 
C' . 2 AAATTCATT'I'CTT OC"TCA'T CTCIC CA*CGO:: CC"l'C'TCCAATAT1C" &'I' 'IGC'IC'l' T 7 ACTCX:'t ICCT 1'GC 'lOX' a::A C c: l' 1'CA. 
ce.l lIGATTCATTTATT GCTCAT CTTIC GA"OOOC CC"l'C'TCCAAtcTTC A AT m:TTT T T = Atee 'ICC TCCC etA T co T CM 
RI.2 ACATTCATTTATT GC'1'CA.T C'lCIC GAIIIIGCGC GG*fI ••• ,AA.'ICT'1C" &'I' '1GC"!C't T T GI:TCCT N::fC 1'OC '!OX GTA C C 'f CCA 
Ra.1 AAATlCA.TTlCTT CCTCAT C"lCIC CA1IIGCXX: ClC"J'C'tCCAATArlC A aT 'lQ:'1C"f T T CX'TTCT ICIC 1'OC 1'CC'T C'TA C c: T eM. 
SI .. 5 11 I I 111111111 TCTTA'f 'fOCAT IG*I.NX ClC"J'C'tCCAA'!C1'GC C -= 1'GC1C'1' C C ICTCX:T N::fC 1CCC c:rA C C T CCA 
SI.1 ••••••• TTTCTT GCTCAT CTCIoC GA"GOX CGTCTl\GAAtcTTC A Ie TIlCTCT T T CGTCCT ~ 'ICC TCCC ClCA CAT CM 
Be.J .... 1CCTCIoGCTCC etATTC = ~ CATCTlICG1CUCC T CA CTCXXX: C T CCNXA Cta: 'ICC CT1C etc C co co AN> 
B' .4 ...... TT .... TTTCTT GTTCAT CTCIoC GA"GOX CC"l'C'TCCAAtcrTC An TIlCTCT T T OCTCTT ~ TCCC AU ceo T cx:A 
Be.5 AIoCTA= CCTTAT TTCAT lOGoa;o:: CC"l'C'TCCAA1'C'TGC A AT 'ICTTCT T T ICTCCT ~ TCCC CTA C co T cx:A 
-+-----+----I 1no 
a' .. l ~TA'tTl"GI:X:ATCA1'CIILIXiGlXLliCIGCA"I'CCA'l'CUIC'1CaA.1'AnTlCXTTA~TACNr.ATICIrGAl\X"!Q:I 
•• • lb CTT l\GAATATTl'CICCA'ICA~ ClCTTC"!QCA1'GG II1IC1I:UATA T 0: A C CN:C C AT C etc TCT C T NrAT C co co It;; T 
.'.2 CTT N;MCATTT~'ICA~ <X:TTCTGCA1'GG A1II:ICUUA T 0: A C CN:C C AT C eTC TO:: C T MX:IC C co co It;; T 
C •• 1 CTT l\GAAUTTT~'ICA~ o::TTCTCCA1'GG II1IC1I:UA"'" T 0: A C CN:C cue eTC TCT C T MX:IC C co co lOG T 
<;1.2 en l\GAAUTTT~'ICA~ <X:TTCTGCA1'GG &1I:lICATATA T 0: A C CN:C C A"t C etc TCT C T NaC C co co It;; T 
<;1.1 CCT IGAGTATTToaA'ICA'lCATCCC ClCTTCTGCA1'GG ~ T CA co T C'!CC CAT C eTC TTT C T MX:IC C co co It;; T 
111.2 en l\GAAUTTTI<X:A~ OCTCClCCATCrO JIIlC'ICATATA T 0: A C GA'II: C et C TCX: TCT C C MX:IC C C C It;; T 
111.1 en l\GAATATTT~T1G1'CAToa <X:TTCTGCA1'GG IIlCII:UllD T 0: A C CA'II: C A"t C eTC TCT T T MX:IC C co co IG T 
S'.5 CCT ICN:TACTTA'lCATCTTCA'n>CT C'lCtC1'GTICIG EDC'I1CAA T 0: A C CTTT T TT T gee TCT T T CA~ C A co a T 
SI.1 CCT ~'ICA'n>CT ~ ata:IC&D T a A C = C Ie C eTC TCT T T MX:IC C C C IG co 
BI.] o:c IICMA%~ lI%Al"lQlCIIGT JIIItDIIITTA co 1'C A C C'!CC A AT C ATe en C C Nrrr T C A It;; C 
.'.4 '!C'1' CCA.*U.tTi'arrA~~ iCllCiGJCUG IIC'KIC1TJlD. l' 0: A C TlC'C C AT C etC 1C1' '!' '!' CICIC C c: Ci ~ '1' .'.5 CCT Ale*TATTTA'lCA1'CC'lCATGCT ocx:TCTerATlG ICTItC1C7A T 0: A C CTTT T AT T ocr; TCT T T a~ C co co a T 
----__ -+ ______ ~------~ ______ +-______ ~~~_+ ____ --~------+-------~----~------~------~I 1'00 
.'.1 A'l'CX:JC'rCICXX~~IGAAG1GAClCa:a:uc:taUC:AA~ 1UX111iClGGl~ 
.'.lb 1'C T <XXlC A'll: IlC co C CA co TC A D A CA C CAIC'I'OCC TT C co A CA a:: co 
.'.2 TC T <XlIlC laO c:r; co C CA co TC A D A a A a:ar::na:: TT C co A CA a:: co 
CI.1 TC T <XXlC Ale c:r; co C CA co TC A D A a C CAIC'I'OCC TT C co A CA lie co 
<;1.2 TA T = Ale c:r; co C CA co 'Ie A D A a A CC#CrNX TT C co A CA a:: co 
<;1.1 TC T <XXlC Ale IlC co C CA co TC A TA A CA C CAIC'I'OCC TT C co A CA a:: co 
111.2 TC T <XlIlC A'll: IlC co A CA co TC A a: A CA C TNXTNX a C co A CA IlC co 
.... 1 TC T C1'GG Ale c:r; co A CA co TC co a: A CA C CHX:1IlCC TT C co A CA a:: co 
II.S TC T CUG Ale c:r; A C cz:: co TC co -= co TA C CMTC1'CC TT C co T 1lC": A 
11.1 'Ie T CCAA ClCA CA co C CA co 'II: a K a CA T c:x=MX TT C co co CA a:: co 
.,.] 0: A UGC IICA c:r; co C CA A AA A E co TA C CMTICTC TT C co A CA At. co .'.4 'II: T aa; IICA IG co C 'II: A TC a a:.. CA C CM1I:A'II: 'II: C co T le lie .. 
• '.5 TC T CUG Ale c:r; A C Ie. CO'll:" -= co TT C CMTT1'CC TT co T T a: II: .. 
1920 
.'.1 '!"l'ClC"'I'CICttTAAc:a":a,,a;rrOCl:A:rJCA.~fC' i i • ft. iI!ATIC'1'CIGC'AJCA.~1C&~ 
.'.lb co CAT TJUICAA AIICIOT1OlCA co TtaGQIOA C a:c 1'C TAA TAT CAT A a C IG C CICA .. 0: 
.'.2 co CU TJUICAA AIICIOT1OlCA co T1ICII:lIlCa C a:c E Tat. T .. T aT" a C IG C C1C& A 0: 
CI.1 co CU TJUICAA ~ co T'I'CIIQQG& C CMI: E TAA T .. T CU.. a C IG C C1C& .. 0: 
<;1.2 co CAT TAICAA  co T1C1oGOI:A C CMI: E TN. T .. 'I CAT" a C IG C CICA .. 0: 
.... 1 co CAT TJUICAA ~ co T'I'CIIQQG& C CMI: 1'C TN. T A 'I CAT.. a C IG C CICA .. 0: 
.... 2 C CAT TAICAA UGCATClCC:A co T'I'CIIQQG& C CMI: E Tat. T co C CAT.. a C IG C CICA .. 0: 
111.1 C CAT TAICAA U<Z;ATClCC:A co T'I'CIIQQG& C CUG U TIC T co T ClCT" a C It; C C1C&" 0: 
11.5 co ClOG <XlQOIlC a:ATCTATTA co ~ C CMI: E t'CA co co 'I GAT co aT It; T 
II .1 co AIC TAICAA COIIGAATC1'CA co T'I'CIIQQG& C CMI: E 'ICA T .. 'I CAT A a C AA C 
a •• 1 C; ox cxxx:.AA. CLlIIiX ,0: Ie c: TICCIQQCA C CUG 1C JGA l' C T CAA l' I(; C II; C 
.'.4 co CAlI. CTCCIG 1'GGICCC1CC co CTCNJGIIG T CAM: TT ICA T co T TAT A a C IlC C .'.5 co ClOG cx:GCIOC t'CATCTATTA A 1CICJGCTA C ac& cz: TGA co co T GAT A CT T lOG C 
I 2040 
.1.1 ~~NXXJtCIQCQC"'!QC:III" iii" iCC,Ci" iGAA"" i". lGi i iOXLl tCttLl1 
.'.1hA 'ICA etc co ace CA T IIX or a CCT TC IC C T 0: C TT 
a'.2 A 'ICA etc cae C CA T IIX or A CCT 1C 0: T T 1C C TT 
CI.1A 'IOCetcCO CTC C CAT IIX TCC co CCT1C OCC T 0: C TT 
<;1.2 A TeA etc cae C CA T IIX CIoC .. CCT Te OC C T 0: C TT 
Q.l A 'lCA C"iC C CT ceCA T Kr. eM A CCT 'IC ""C C T ex:: C TT 
1ta.2 A ocr; etc c CT ceCA T IIX or A ClCT 1C OC C T 0: C TT 
1lI . 1 A '10: CTC C C1' ceCA T Kr. ax: A a:T 'IC -c C T ex:: C TT 
C'.1 a. 1'CA C"iC C C'r ceCA T A/IC ca: A CC . .. . 
8'.1 A TeA C'IG C Tr T T TC T GCT ox A 10:: ex: 
R • • t A TTG ax:.. TT ceCA C TCC CIoC T COl CT 
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